Clinical trial NCT02515097
Conditions: Plaque Psoriasis
Sponsor: Bausch Health Americas, Inc.
Start date: 2015-11-05; Completion date: 2017-03-15
Enrollment: 213 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study is to evaluate the safety and efficacy of a topical lotion when applied once daily to adult participants with moderate to severe plaque psoriasis (defined as an Investigator's Global Assessment \[IGA\] score of 3 or 4).

Detailed description:
The objective of the study is to evaluate the safety and efficacy of topical IDP-122 Lotion when applied once daily to adult participants with moderate to severe plaque psoriasis. The intent of the study is specifically to evaluate the safety and efficacy of a once daily application of IDP-122 Lotion in comparison with vehicle.

Arms: arm 1: Participants will apply IDP-122 Lotion (halobetasol propionate \[HP\] 0.01%) topically once daily for 8 weeks. arm 2: Participants will apply IDP-122 Vehicle Lotion topically once daily for 8 weeks.
Interventions: intervention 1: IDP-122 Lotion intervention 2: IDP-122 Vehicle Lotion
Intervention descriptions: intervention 1: Medicated topical lotion intervention 2: Vehicle topical lotion with no active ingredient

Protocol documents:
Prot_SAP_000.pdf: 
Clinical Study Protocol 
IDP-122
Protocol V01-122A-302 
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle 
Controlled Clinical Study to Assess the Safety and Efficacy of 
IDP-122 in the Treatment of Plaque Psoriasis 
Development phase of study: 
3 
Study design: 
Multicenter, Double-Blind, Randomized, 
Vehicle Controlled Clinical Study 
Date: Original 
Amendment 1 
14 July 2015 
14 October 2015 
Sponsor: 
Dow Pharmaceutical Sciences, a Division 
of Valeant Pharmaceuticals North 
America, LLC 
1330 Redwood Way 
Petaluma, CA 94954 
CONFIDENTIAL 
Nothing herein is to be disclosed without prior approval of the sponsor. 
NCT#: NCT02515097




Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
3
Personnel Responsible for Conducting the Study 
A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study 
to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis 
Contract Research Organization 
 
  
Cu-Tech, LLC 
333 Route 46 West 
Mountain Lakes, NJ 07046 
 
 
 
t 
Cu-Tech, LLC 
333 Route 46 West 
Mountain Lakes, NJ 07046 
 
 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
4
Principal Investigator Protocol Agreement Page 
I agree: 
x To assume responsibility for the proper conduct of this clinical study at this site and to 
conduct the study in compliance with this protocol, any future amendments, and with 
any other study conduct procedures provided by the sponsor. 
x That I am aware of, and will comply with, the internationally recognized code of Good 
Clinical Practices (GCP) and all other applicable regulatory requirements to obtain 
written and dated approval from the Institutional or Central Review Board (IRB) or 
Independent Ethics Committee (IEC) for the study protocol, written informed consent, 
consent form updates, subject-recruitment procedures (e.g., advertisements), and any 
other written information to be provided to the subjects, before initiating this clinical 
study.
x Not to implement any changes to, or deviations from the protocol without prior 
agreement from the sponsor and review and documented approval from the IRB/IEC, 
except to eliminate an immediate hazard to the study subjects, or when change(s) 
involves only logistical or administrative aspects of the clinical study. 
x To permit direct monitoring and auditing by the sponsor or sponsor’s representatives 
and inspection by the appropriate regulatory authority(ies). 
x That I am thoroughly familiar with the appropriate use of the investigational 
products(s), as described in this protocol, and any other information provided by the 
sponsor or designee, including, but not limited to, the current Investigator Brochure or 
equivalent document and approved product label (if applicable). 
x To provide sufficient time, and adequate numbers of qualified staff and facilities for the 
foreseen duration of the clinical study to conduct the study properly, ethically, and 
safely.
x To ensure that all persons assisting in this study are adequately informed about the 
protocol, investigational product(s), and their clinical study related duties and 
functions.
Principal Investigator (print name) 
 
Principal Investigator (signature) 
 
Date 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
5
2 Synopsis
Name of Sponsor/Company: Dow Pharmaceutical Sciences, a division of Valeant Pharmaceuticals North 
America, LLC
Name of Investigational Product: IDP-122 Lotion
Name of Active Ingredients: Halobetasol propionate (HP) 0.01% w/w 
Title of Study: A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to 
Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis 
Number of clinical centers: Multicenter, approximately 12-16 investigational centers in North America 
Objective: 
The objective of the study is to evaluate the safety and efficacy of topical IDP-122 Lotion when applied once 
daily to adult subjects with moderate to severe plaque psoriasis (defined as an Investigator’s Global 
Assessment [IGA] score of 3 or 4). The intent of the study is specifically to evaluate the safety and efficacy of 
a once daily application of IDP-122 Lotion in comparison with vehicle. 
Methodology: 
This is a multicenter, double-blind, randomized, parallel-group study designed to assess the safety, tolerability, 
and efficacy of IDP-122 Lotion in comparison with vehicle. To be eligible for the study, subjects must be at 
least 18 years of age and have a clinical diagnosis of moderate to severe psoriasis (defined as an IGA score of 
3 or 4). 
Approximately 210 subjects who meet the study entry criteria will be randomized in a 2:1 ratio to receive 
IDP-122 (HP 0.01%) Lotion and IDP-122 Vehicle Lotion, respectively. Two containers of the assigned study 
drug will be dispensed to the subject at the Baseline visit. The study drug will be applied topically to the 
affected areas (as determined by the investigator at baseline) once daily for 8 weeks. The initial application 
will be made by the subject per instruction from the study staff.  The subjects will be instructed to avoid 
exposure to direct sunlight, artificial ultraviolet light sources and to use protective clothing to prevent sunburn. 
Subjects will apply their once daily treatments at home as explained by the study coordinator or designee at 
each investigational center. 
The study coordinator, or designee at each investigational center will dispense 2 new containers of study drug 
to each subject at Baseline and Weeks 2, 4, and 6. During post-baseline study visits (Weeks 2, 4, 6, and 8) the 
subjects will be asked to return their containers of study drug which will be evaluated for drug usage 
compliance. Upon completion of the 8-week treatment period, all subjects will be asked to return to the 
investigational center 4 weeks later for a post-treatment cessation follow-up visit (Week 12). During the study, 
subjects will be allowed to use investigator approved non-medicated cleansers, moisturizers and sunscreens; 
no other skin care products will be permitted on the treatment areas. The investigator will assess the areas 
affected by psoriasis at each study visit. 
All areas affected by psoriasis (with an affected body surface area [BSA] of 3%-12%, inclusive) are to be 
treated with study drug. The affected areas (3%-12% BSA) will not include face, scalp, palms, soles, groin, 
axillae, and intertriginous areas. Information on reported and observed adverse events (AEs) will be obtained 
at each visit. An abbreviated physical examination will be performed at Baseline, Week 8 (end of treatment), 
and Week 12 (4-week post-treatment cessation follow-up visit) for all subjects. 
Blood samples for complete blood count with differential (CBC/Diff) and serum chemistry will be collected 
from subjects at Screening, Week 4, and Week 8. For all female subjects of childbearing potential, urine and 
serum pregnancy testing will be performed at Screening. Urine pregnancy testing will be performed at 
Baseline (prior to randomization) and Week 12 (4-week post-treatment follow-up visit), and serum pregnancy 
testing will also be conducted at Week 4 and Week 8. 
Subjects who terminate study participation early will be asked to complete all Week 8 assessments, as 
appropriate, prior to commencement of any alternative therapy for psoriasis (if possible). Subjects who 
discontinue from the study during the treatment period will not be replaced and these subjects may be asked to 
return for the 4-week follow-up visit after the last treatment visit. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
6
If signs or symptoms develop in the selected treatment areas during the treatment period that restrict daily 
activities or make continued application of the study drug difficult due to discomfort, the investigator may 
instruct the subject to temporarily interrupt use of the study drug and to resume application of the study drug 
once the signs/symptoms have subsided. The investigator should try to minimize study drug interruptions; and 
if needed, make best efforts to limit a “drug holiday” to 4 days. If the study drug interruption does exceed 
4 consecutive days, the investigator should consult with the medical monitor to determine a course of action. If 
the study drug is interrupted, discontinued, or a concomitant medication is used to treat a sign/symptom, an 
adverse event shall be recorded. 
Subjects who discontinue from the study, due to clinically significant laboratory abnormalities or AEs will 
return for the 4-week follow-up visit after the last treatment visit and will be instructed to follow-up with their 
primary care physician, if indicated. If any subject who has an AE, during the treatment period, the subject 
will be followed by the investigator until resolution (return to normal or to the baseline state) or stabilization, 
as determined by the investigator. 
In addition, application of study drug may be delayed or halted at any time if ongoing safety data evaluations 
(including reports of local skin reactions, such as skin atrophy, or severe AEs) raise concern for subject safety. 
If the subject participation is suspended, all of the subject’s safety data will be reviewed by the medical 
monitor in conjunction with the investigator to determine course of action. 
Number of subjects planned: 
Approximately 210 adult subjects (approximately 15 subjects per investigational center) with moderate or 
severe psoriasis (defined as an IGA score of 3 or 4) will be enrolled and randomized in the study. With a 
2:1 randomization ratio, it is anticipated that: 
x 
Approximately 140 subjects will be randomized to receive IDP-122 (HP 0.01%) Lotion 
x 
Approximately 70 subjects will be randomized to receive IDP-122 Vehicle Lotion 
Diagnosis and main criteria for inclusion: 
1. Male or female, of any race, at least 18 years of age. 
2. Freely provides both verbal and written informed consent. 
3. Has an area of plaque psoriasis appropriate for topical treatment that covers a BSA of at least 3%, but no 
more than 12%. The face, scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this 
calculation.
4. Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4. (The face, scalp, 
palms, soles, axillae, and intertriginous areas are to be excluded from this assessment, if psoriasis is 
present). 
5. Has a target lesion that meets the following criteria:  
x 
Measures between 16-100 cm2 inclusive
x 
Has a score of at least 3 for at least 2 of the 3 different psoriasis signs (erythema, plaque elevation, 
and scaling); with a sum of the three scores at least eight (8), and cannot have a score of 0 or 1 for 
any one of the signs 
x 
Target lesions cannot be on excluded areas or areas covering bony prominences (i.e., elbows and 
knees) 
6. Is in good general health based on the subject’s medical history and a physical examination, Screening 
hematology and serum chemistry laboratory values within normal range or not clinically significant as 
determined by the investigator. 
7. If female and of childbearing potential, must have a negative urine and serum pregnancy test at the 
Screening visit and negative urine pregnancy at Baseline visit prior to randomization. 
8. If female, is either not of childbearing potential, defined as postmenopausal for at least 12 months or 
surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy), or is of childbearing 
potential and practicing 1 of the following methods of birth control throughout the study: 
x 
Condom with spermicide, diaphragm with spermicide, intrauterine device, or abstinence 
x 
Stable use of a hormonal contraceptive (oral, implant, insertable, injection or transdermal patch) for at 
least 3 months prior to the Baseline visit. 
9. Subject is willing to comply with study instructions and return to the clinic for required visits. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
7
Key exclusion criteria: 
1. Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular psoriasis, as determined 
by the investigator. 
2. Presents with psoriasis that was treated with prescription medication and failed to respond to treatment, 
even partially or temporarily, as determined by the investigator. 
3. Presents with any concurrent skin condition that could interfere with the evaluation of the treatment areas, 
as determined by the investigator. 
4. Is pregnant, nursing an infant, or planning a pregnancy during the study period. 
5. Has received treatment with any investigational drug or device within 60 days or 5 drug half-lives 
(whichever is longer) prior to the Baseline visit, or is concurrently participating in another clinical study 
with an investigational drug or device. 
6. Received treatment with any topical antipsoriatic drug product within 14 days prior to the Baseline visit. 
7. Has used any phototherapy (including laser), photochemotherapy, or non-biologic systemic psoriasis 
therapy (such as newer oral psoriasis medications (eg Otezla), systemic corticosteroids, methotrexate, 
retinoids or cyclosporine) within 4 weeks prior to the Baseline visit. 
8. Has used immunomodulatory therapy (biologics) known to affect psoriasis within 3 months of the 
Baseline visit. 
9. Has had prolonged exposure to natural or artificial sources of ultraviolet radiation within 4 weeks prior to 
the Screening visit or is intending to have exposure during the study thought likely by the investigator to 
modify the subject’s psoriasis. 
10. Is currently using lithium or Plaquenil. 
11. Has a history of hypersensitivity or allergic reaction to any of the study drug constituents. 
12. Is unable to be compliant with study procedures, study drug administration requirements, study visit 
schedules, and prohibitions regarding the use of concomitant medications/therapies. 
13. Is unable to communicate or cooperate with the investigator. 
14. Has any underlying disease that the investigator deems uncontrolled that poses a concern for the subject’s 
safety while participating on the study. 
15. Has a history of drug or alcohol abuse. 
16. Is considered by the investigator, for any other reason, to be an unsuitable candidate for the study.
Investigational product, dosage and mode of administration: 
IDP-122 Lotion, applied topically, once daily for 8 weeks. 
Application Instructions: 
The investigational center staff member will instruct the subject to apply the study drug to the affected 
treatment areas identified at the Baseline visit by the investigator. The staff member will instruct the subject on 
the proper application procedure during the Baseline visit. Subjects will be instructed to squeeze a small 
amount of study drug (about the size of a pea) onto a fingertip and then spread a thin layer of the study drug 
over the affected treatment area. If necessary, additional pea-sized amounts of study drug may be applied in 
increments to cover all affected treatment areas as designated by the investigator. In addition to the verbal 
instructions given during the visit, the subjects will be provided with written instructions. 
Subjects will be instructed to apply a thin layer of study drug to the entire selected treatment area(s) as 
indicated on the body diagram at home once daily up to the Week 8 visit. Subjects will be advised to avoid or 
minimize exposure to direct sunlight and artificial ultraviolet light sources while in the study and to wash their 
hands before and after application of the study drug. 
The amount of study drug used by the subjects will be monitored by weighing each newly dispensed study 
drug container and re weighing each returned study drug container at all applicable study visits. The maximum 
allowable weekly usage is 50 grams for this study. 
Duration of treatment:
8 weeks for all subjects 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
8
Reference therapy, dosage and mode of administration: 
IDP-122 Vehicle Lotion, applied topically, once daily for 8 weeks. 
The reference therapy (IDP-122 Vehicle Lotion) will be applied in the same manner as described for the 
investigational product (IDP-122 Lotion). 
Criteria for evaluation: 
A summary of the study measurements follows. Note that for all efficacy measurements, the 
investigators/evaluators will be provided with training to ensure consistent evaluations across investigational 
centers. To the greatest extent possible, the assessments for a particular subject should be performed by the 
same sponsor-approved evaluator at all study visits. 
Safety Measurements:
Local Skin Reactions: Tolerability will be evaluated through assessments of selected local signs and symptoms 
(itching, dryness, burning/stinging). In addition, the treatment areas will be examined at each visit by the 
evaluator for the presence or absence of significant known drug-related AEs; skin atrophy, striae, 
telangiectasia, and folliculitis. Any local skin reaction requiring use of a concomitant therapy or is a cause for 
study drug interruption or discontinuation should be reported as an adverse event. The scales to be used for 
assessing local skin reactions follow: 
Score  
Grade  
Description 
Itching: as reported by the subject within the last 24 hours 
0 
None 
No itching 
1 
Mild 
Slight itching, not really bothersome 
2 
Moderate 
Definite itching that is somewhat bothersome 
3 
Severe 
Intense itching that may interrupt daily activities and/or sleep 
Dryness: as assessed by the investigator 
0 
None 
No dryness 
1 
Mild 
Slight, but definite roughness 
2 
Moderate 
Definite roughness 
3 
Severe 
Marked roughness 
Burning/Stinging: as reported by the subject within the last 24 hours 
0 
None 
No burning/stinging  
1 
Mild 
Slight burning/stinging sensation; not really bothersome 
2 
Moderate 
Definite warm, burning/stinging that is somewhat bothersome 
3 
Severe 
Hot burning/stinging sensation that causes definite discomfort and may interrupt 
daily activities and/or sleep 
 
 
 
 
 
 
 
 
 
 
 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
9
All of the below will be assessed by the investigator as present or absent.
Skin Atrophy: 
No 
Skin atrophy not present 
Yes 
Skin atrophy present 
Striae:
No 
Striae not present 
Yes 
Striae present 
Telangiectasias: 
No 
Telangiectasias not present 
Yes 
Telangiectasias present 
Folliculitis: 
No 
Folliculitis not present 
Yes 
Folliculitis present 
Adverse Events: During the study, subjects will be assessed for the occurrence of new and ongoing AEs. 
Descriptions of AEs will include the dates of onset and resolution (if resolved), maximum severity, 
seriousness, action taken regarding the study drug, corrective treatment, outcome, and the investigator’s 
assessment of causality. AEs present at any visit will be followed to resolution (return to normal or to the 
baseline state) or until clinically stable as determined by the investigator. 
Safety Laboratory Tests: Routine safety laboratory tests (CBC/Diff and serum chemistry) will be performed at 
Screening, Week 4, and Week 8. Any out-of-range laboratory result that is considered clinically significant by 
the investigator will be recorded as an AE and should be confirmed by repeat testing at the discretion of the 
investigator. Clinically significant laboratory abnormalities at any visit will be followed to resolution (return to 
normal or to the baseline state) or until clinically stable as determined by the investigator. 
Pregnancy Tests: All female subjects of childbearing potential will undergo serum pregnancy testing at 
Screening, Week 4, and Week 8. In addition, urine pregnancy testing will be performed at Screening, Baseline 
(prior to randomization), and Week 12 (4-week post-treatment follow-up visit). 
Abbreviated Physical Examinations: An abbreviated physical examination will be performed at Baseline, 
Week 8, and Week 12 (4-week post-treatment follow-up visit). 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
10 
Efficacy Measurements: 
Investigator’s Global Assessment: The IGA is based on a 5-point scale ranging from 0 (clear) to 4 (severe), 
and will be assessed by the evaluator at each visit for the overall affected areas with plaque psoriasis. The face, 
scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this assessment. The following scores 
will be used to describe the severity of overall psoriasis of the treatable areas: 
Grade 
Score 
Description  
Clear 
0 
No evidence of scaling 
No evidence of erythema 
No evidence of plaque elevation above normal skin level 
Almost 
Clear
1 
Some plaques with fine scales 
Faint pink/light red erythema on most plaques 
Slight or barely perceptible elevation of plaques above normal skin level 
Mild 
2 
Most to all plaques have some fine scales but are not fully covered, some plaques 
are completely covered with fine scale 
Most to all plaques are pink/light red to bright red in color 
Some plaques have definite elevation above normal skin level, typically with edges 
that are indistinct and sloped on some of the plaques 
Moderate 
3 
Some plaques are at least partially covered with a coarse scale, most to all plaques 
are nearly covered with fine or course scale; 
Most to all plaques are bright red, some plaque may be dark red in color 
Definite elevation of most to all plaques; rounded or sloped edges on most of the 
plaques 
Severe 
4  
Most to all plaques are covered with coarse, thick scales 
Most or all plaques are bright, dark or dusky red 
Almost all plaques are raised and well-demarcated; sharp edges on virtually all 
plaques  


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
11 
Psoriasis Signs: The signs of psoriasis (erythema, plaque elevation, and scaling) will be assessed by the 
evaluator using the following scales for the selected target lesion: 
Score  
Grade  
Description 
Erythema: 
0 
None 
No erythema  
1 
Minimum 
Pink discoloration, minimal erythema 
2 
Mild 
Most plaques are light red to red in color 
3 
Moderate 
Most or all plaques are bright red or dark red in color 
4 
Severe 
Most plaques dusky red with purple hue 
Plaque Elevation: 
0 
None 
No evidence elevation above the normal skin level 
1 
Minimum 
Slight, just discernible elevation above normal skin level 
2 
Mild 
Some plaques show definite elevation with indistinct edges 
3 
Moderate 
Most plaques have definite elevation with distinct edges that are rounded or 
sloped 
4 
Severe 
Almost all plaques are raised above normal skin level with sharp edges 
Scaling: 
0 
None 
No scales on very few plaques 
1 
Minimum 
Occasional fine scales hardly noticeable 
2 
Mild 
Most plaques have fine scales 
3 
Moderate 
Some plaques have coarse scales while most plaques have fine scales 
4 
Severe 
Most plaques are covered by thick coarse scales 
Other Evaluations:  
Questionnaire: The Dermatology Life Quality Index (DLQI) questionnaire will be administered to subjects at 
Day 0 (Baseline), Week 4, Week 8/End of Treatment and Week 12 (4-week post-treatment follow-up visit). 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
12 
Statistical methods:
All subjects who are randomized and dispensed study drug will be included in the intent-to-treat (ITT) analysis 
set. All subjects in the ITT analysis set who complete the Week 8 visit without any major protocol violations 
will be included in the per protocol (PP) analysis set. All subjects who are randomized, receive at least 
1 confirmed dose of study drug, and have at least 1 post-baseline assessment will be included in the safety 
analysis set. 
The ITT analysis set will be considered primary for the evaluation of efficacy. The primary method of 
handling missing efficacy data will be the method of Markov Chain Monte Carlo (MCMC) multiple 
imputation; no imputations will be made for missing safety data. 
 
Efficacy:
Efficacy Endpoints 
The efficacy endpoints are intended to compare once daily application of IDP-122 Lotion and vehicle. 
Specifically, the efficacy endpoints include: 
x 
The percent of subjects with treatment success, defined as at least a 2 grade improvement from 
Baseline in the IGA score and an IGA score equating to “clear” or “almost clear” at Weeks 2, 4, 6, 8 
and Week 12 (4-week follow-up), as summarized using descriptive statistics. 
x 
The percent of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Weeks 2, 4, 6, 8 and Week 12 (4 week 
FU), as summarized using descriptive statistics for the target lesion treated with study drug. 
Inferential Statistics 
Primary Efficacy 
The primary efficacy endpoint will be the percent of subjects with treatment success, defined as at least a 
2-grade improvement from Baseline in IGA score and an IGA score equating to “Clear” or “Almost Clear”. 
The primary efficacy endpoint will be used to compare once daily application of IDP-122 Lotion with its 
vehicle. The percent of subjects with treatment success at Week 8 will be analyzed using Cochran-Mantel-
Haenszel (CMH) tests stratified by analysis center.  
Secondary Efficacy 
Similar to the primary endpoint analyses, pairwise comparisons will be performed using CMH tests stratified 
by analysis center. The secondary efficacy endpoints will be: 
x 
Percentage of subjects who show at least a 2 grade improvement and reach Clear to Almost Clear at 
Week 12 for IDP-122 Lotion versus IDP-122 Vehicle Lotion 
x 
Percentage of subjects who show at least a 2 grade improvement and reach Clear to Almost Clear at 
Week 6 for IDP-122 Lotion versus IDP-122 Vehicle Lotion 
x 
Percentage of subjects who show at least a 2 grade improvement and reach Clear to Almost Clear at 
Week 4 for IDP-122 Lotion versus IDP-122 Vehicle Lotion 
x 
Percentage of subjects who show at least a 2 grade improvement and reach Clear to Almost Clear at 
Week 2 for IDP-122 Lotion versus IDP-122 Vehicle Lotion 
Evaluation of the secondary efficacy variables will use a gated sequential procedure starting with the 
comparisons of the first bulleted item and proceeding onto the next item. The process will terminate if a 
nonstatistically significant value is observed. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
13 
Tertiary Efficacy 
The follow tertiary efficacy endpoints will be analyzed to further characterize the treatment effect of IDP-122 
Lotion over the IDP-122 Vehicle Lotion. The analyses will use CMH testing stratified by analysis center 
without adjusting for multiplicity. 
x 
Percentage of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Week 12 for the target lesion 
x 
Percentage of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Week 8 for the target lesion 
x 
Percentage of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Week 6 for the target lesion 
x 
Percentage of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Week 4 for the target lesion 
x 
Percentage of subjects with at least a 2-grade improvement from Baseline in the score for each of the 
signs of psoriasis (erythema, plaque elevation, and scaling) at Week 2 for the target lesion 
Safety: 
Subjects will be assessed for the occurrence of new and ongoing AEs. Descriptions of AEs will include the 
dates of onset and resolution (if resolved), maximum severity, seriousness, action taken regarding the study 
drug, corrective treatment, outcome, and investigator’s assessment of causality. All AEs will be recorded and 
classified using terminology from the Medical Dictionary for Regulatory Activities (MedDRA). All reported 
treatment-emergent AEs (TEAEs), defined as any AE with an onset on or after the date of first study drug 
application, will be summarized by treatment group, the number of subjects reporting TEAEs, system organ 
class, preferred term, severity, and relationship to study drug. When summarizing TEAEs by severity or 
relationship to study drug, each subject will be counted only once within a system organ class or a preferred 
term using the event with the greatest severity or causality, respectively, within each category. All reported 
serious adverse events (SAEs) will be summarized by treatment group, the number of subjects reporting SAEs, 
system organ class, preferred term, severity, and relationship to study drug. 
All information pertaining to AEs noted during the study will be listed by subject and will include a verbatim 
description of the event as reported by the investigator, as well as the preferred term, system organ class, start 
date, stop date (if stopped), seriousness, severity, action taken regarding the study drug, corrective treatment, 
outcome and relationship to the study drug. In addition, a listing of subjects who prematurely discontinue from 
the study due to AEs will be provided as well as a listing of subjects who reported an SAE. 
The frequency of local skin reactions including itching, dryness, burning/stinging, skin atrophy, striae, 
telangiectasia and folliculitis will be summarized by treatment group and visit. Additionally, the percent of 
subjects who experience a local skin reaction (itching, dryness, burning/stinging) graded at a level of 3, at any 
point in the study following the first application of study drug, will be tabulated by treatment group.  Changes 
from baseline in safety laboratory values and vital sign measurements will be summarized with descriptive 
statistics for each treatment group at all applicable study visits. 
Shift tables will be presented for changes in safety laboratory values to summarize laboratory test results 
collected at Baseline and Weeks 4 and 8. Normal ranges established by the central laboratory will be used to 
determine the shifts. A listing of all out-of-range laboratory test results at any assessment time point will also 
be provided. Determination of clinical significance for all out-of-range laboratory values will be made by each 
investigator and included in the listing. In addition, a listing of all clinically significant laboratory test results 
will be provided. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
14 
Sample size calculations:  
One hundred forty (140) IDP-122 treated subjects and seventy (70) vehicle treated subjects will have greater 
than 95% power to detect a statistically significant outcome for a two-sided test with an alpha level of 0.05. 
This is based on treatment success rates of 33.3% and 9.7% which were observed in V01-118A-201. Success 
was defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score equating to 
“Clear” or “Almost Clear”. 
This study will be performed in compliance with GCP including the archiving of essential study documents. 
This protocol follows guidelines outlined by the International Conference on Harmonization (ICH). All data 
furnished to the investigator and his/her staff, and all data obtained through this stud, will be regarded as 
confidential and proprietary in nature and will not be disclosed to any third party, except for the United States 
Food and Drug Administration or other regulatory body, without written consent from the sponsor. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
15 
3 Table of Contents 
1 
TITLE PAGE ...........................................................................................................1
2 
SYNOPSIS ...............................................................................................................5
3 
TABLE OF CONTENTS .......................................................................................15
4 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ........................19
5 
INTRODUCTION .................................................................................................20
6 
STUDY OBJECTIVES AND PURPOSE .............................................................20
7 
INVESTIGATIONAL PLAN ................................................................................21
7.1 
Overall Study Design and Plan: Description .............................................21
8 
SELECTION AND WITHDRAWAL OF SUBJECTS .........................................24
8.1 
Subject Inclusion Criteria ..........................................................................24
8.2 
Subject Exclusion Criteria .........................................................................25
8.3 
Subject Withdrawal Criteria ......................................................................26
9 
TREATMENT PLAN ............................................................................................27
9.1 
Methods of Assigning Subjects to Treatment Groups ...............................27
9.2 
Randomization and Blinding .....................................................................27
9.3 
Unblinding .................................................................................................28
9.4 
Prior and Prohibited Concomitant Medication or Therapy........................28
9.5 
Treatment Compliance ...............................................................................29
9.6 
Protocol Deviations and Violations ...........................................................29
10 
STUDY DRUG MATERIALS AND MANAGEMENT ......................................30
10.1 
IDP-122 Lotion and IDP 122 Vehicle Lotion ............................................30
10.1.1 Packaging and Labeling .................................................................30
10.1.2 Storage, Handling, and Disposal of Study Drug ............................31
10.1.3 Administration ...............................................................................31
10.2 
Study Drug Accountability ........................................................................32
11 
STUDY PROCEDURES AND EVALUATIONS ................................................32
11.1 
Schedule of Evaluations and Procedures ...................................................32
11.1.1 Screening Visit (Day -35 to Day -1) ..............................................32
11.1.2 Baseline Visit (Day 0) ....................................................................34
11.1.3 Week 2 (Day 14 ± 3 Days), Week 4 (Day 28 ± 3 Days), Week 
6 (Day 42 ± 3 Days) Visits ............................................................35
11.1.4 Week 8 (Day 56 ± 5 Days) End of Treatment – Perform these 
Visit Procedures for Subjects who Discontinue Treatment 
Early ...............................................................................................36


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
16 
11.1.5 Week 12 (Day 84 ± 7 Days) – 4-Week Post-Treatment 
Cessation Follow-Up Visit .............................................................37
11.2 
Evaluation of Efficacy ...............................................................................38
11.2.1 Body Surface Area Affected by Psoriasis (BSA) ..........................38
11.2.2 Investigator’s Global Assessment (IGA) .......................................38
11.2.3 Psoriasis Signs ...............................................................................39
11.3 
Evaluation of Safety ...................................................................................40
11.3.1 Localized Skin Reactions ...............................................................40
11.3.2 Medical History and Abbreviated Physical Examination ..............41
11.3.3 Safety Laboratory Tests .................................................................41
11.3.4 Pregnancy Tests .............................................................................42
11.4 
Other Evaluations.......................................................................................42
11.4.1 Dermatology Life Quality Index (DLQI) ......................................42
11.5 
Adverse Events ..........................................................................................42
11.5.1 Definition of Adverse Event ..........................................................42
11.5.2 Documenting Adverse Experiences ...............................................42
11.5.3 Serious Adverse Events .................................................................43
11.5.4 Assessment of Severity ..................................................................44
11.5.5 Assessment of Causality ................................................................44
11.5.6 Reporting of Serious Adverse Events ............................................44
11.5.7 Expedited Serious Adverse Event Reports ....................................45
11.5.8 Laboratory Test Abnormalities ......................................................45
11.5.9 Pregnancy .......................................................................................46
12 
STATISTICS .........................................................................................................46
12.1 
Assessment of Efficacy ..............................................................................47
12.1.1 Primary Efficacy ............................................................................47
12.1.2 Secondary Efficacy ........................................................................47
12.1.3 Tertiary Efficacy ............................................................................48
12.1.4 Pooling Analysis ............................................................................48
12.1.5 Missing Efficacy Data Imputations ...............................................50
12.1.6 Sensitivity Efficacy Analyses ........................................................51
12.1.6.1 Analyses Using Last Observation Carried Forward......51
12.1.6.2 Repeated Measures Analysis on Observed Data ...........51
12.1.7 Subgroup Analyses ........................................................................51
12.2 
Assessment of Safety .................................................................................51
12.2.1 Adverse Events ..............................................................................51
12.2.2 Local Skin Reactions .....................................................................52
12.2.3 Safety Laboratory Values and Vital Sign Measurements ..............52


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
17 
12.3 
Subject Disposition ....................................................................................52
12.4 
Demographics and Baseline Characteristics ..............................................52
12.5 
Protocol Deviations ....................................................................................52
12.6 
Compliance ................................................................................................53
12.7 
Interim Analyses ........................................................................................53
12.8 
Additional Statistical Considerations .........................................................53
12.8.1 Analysis Populations ......................................................................53
12.8.2 Sample Size Determination ............................................................54
12.8.3 Handling of Missing Data ..............................................................54
12.8.4 Multicenter Issues ..........................................................................55
12.8.5 Multiplicity Issues ..........................................................................55
12.8.6 Windowing Rules...........................................................................55
13 
QUALITY CONTROL AND QUALITY ASSURANCE .....................................55
13.1 
Study Monitoring .......................................................................................55
13.2 
Audits and Inspections ...............................................................................56
13.3 
Data Quality Assurance .............................................................................56
14 
ETHICS AND ADMINISTRATIVE ISSUES ......................................................56
14.1 
Ethical Conduct of the Study .....................................................................56
14.2 
Ethics Review ............................................................................................57
14.3 
Written Informed Consent .........................................................................57
14.4 
Subject Data Protection..............................................................................58
14.5 
Data Monitoring Committee ......................................................................58
14.6 
Financial Disclosure ...................................................................................58
14.7 
Investigator Obligations .............................................................................58
14.8 
Changes to the Protocol .............................................................................58
14.9 
Confidentiality/Publication of the Study ...................................................58
15 
DATA HANDLING AND RECORD KEEPING .................................................59
15.1 
Inspection of Records ................................................................................59
15.2 
Retention of Records ..................................................................................60
16 
REFERENCES ......................................................................................................60
17 
APPENDICES .......................................................................................................61
17.1 
Subject Instruction Sheet ...........................................................................61
17.2 
Cleanser, Moisturizer and Sunscreen Use Guidelines ...............................62
17.3 
Dermatology Life Quality Index (DLQI) Questionnaire ...........................63
17.4 
Amendment Summary of Changes ............................................................64


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
18 
LIST OF TABLES 
Table 1. 
Study Design and Schedule of Assessments ..................................................23
Table 2. 
Investigator’s Global Assessment Scale .........................................................38
Table 3. 
Psoriasis Signs ................................................................................................39
Table 4. 
Localized Skin Reaction Scales ......................................................................40
Table 5. 
Percent Dichotomized IGA Success for Treatment Groups ...........................54


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
19 
4 List of Abbreviations and Definitions of Terms 
Abbreviation or Specialist Term 
Definition or Explanation 
AE 
Adverse event 
BSA
Body surface area 
CBC/Diff
Complete blood count with differential 
CMH 
Cochran-Mantel-Haenszel 
eCRF
Electronic Case Report Form 
DLQI
Dermatology Life Quality Index questionnaire 
ET 
Early termination 
FDA
United States Food and Drug Administration 
GCP 
Good Clinical Practice
HP 
Halobetasol propionate 
ICH
International Conference on Harmonization 
IEC 
Independent Ethics Committee 
IGA 
Investigator’s Global Assessment 
IRB
Institutional Review Board 
ITT 
Intent-to-treat 
LOCF 
Last observation carried forward 
MCMC 
Markov Chain Monte Carlo 
MedDRA 
Medical Dictionary for Regulatory Affairs 
PP 
Per protocol 
SAE 
Serious adverse event 
TEAE 
Treatment-emergent adverse event  
In this protocol, “sponsor duties” refer to responsibilities that will be performed by the 
sponsor, the sponsor’s designee, or the sponsor’s designated contract research organization. 
In this protocol, “investigator” refers to the principal investigator or his/her designee, who is 
responsible for performing the study procedures and assessments. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
20 
5 Introduction
Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. 
Disease severity ranges from mild (limited number of plaques) to very severe. Characteristic 
features of psoriasis include hyperproliferation of epidermal cells associated with 
dermal/epidermal inflammation, resulting in sharply demarcated red plaques, which may be 
covered by silvery scales affecting the skin and scalp. 
There are presently no curative treatments for psoriasis. Treatment options focus on relieving 
symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the 
disease. Patient age, severity of disease, and the type and extent of body surface area (BSA) 
involvement are considerations in selecting therapy. 
Biologic treatments are now either available or in development to treat psoriasis. However, 
these treatments are not typically used for mild disease, and their safety profile is not entirely 
well understood. 
Topical therapies are used in all disease severities, but may be impractical when psoriasis 
involves a large BSA. The mainstay of psoriasis treatment is topical corticosteroids, which 
range in potency from superpotent to low potency (Class I to Class VII, respectively). 
Generally, the more potent corticosteroids are required for effective management of 
psoriasis.
Although topical corticosteroids are very effective, long-term safety remains a concern, 
particularly with the more potent ones. Adverse effects such as skin atrophy, telangiectasia, 
and potential hypothalamic-pituitary-adrenal axis suppression have been associated with 
higher potency topical corticosteroids and prolonged treatment. Ultravate® cream and 
ointment (halobetasol propionate [HP] 0.05%) is currently on the market and are classified as 
super-high potency (Class I) corticosteroids indicated for the relief of the inflammatory and 
pruritic manifestations of corticosteroid-responsive dermatoses.  
Having a lower concentration product that is a Class I steroid might be advantageous for 
patients, as the steroid provides relief from inflammation, and may reduce the adverse 
reactions associated with a steroid (eg, skin atrophy). 
6 Study Objectives and Purpose 
The objective of the study is to evaluate the safety and efficacy of topical IDP-122 Lotion 
when applied once daily to adult subjects with moderate to severe plaque psoriasis (defined 
as an Investigator’s Global Assessment [IGA] score of 3 or 4). The intent of the study is 
specifically to evaluate the safety and efficacy of a once daily application of IDP-122 Lotion 
in comparison with vehicle. 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
21 
7 Investigational plan 
7.1 
Overall Study Design and Plan: Description 
This is a multicenter, double-blind, randomized, parallel-group study designed to assess the 
safety and efficacy of IDP-122 Lotion in comparison with its vehicle. To be eligible for the 
study, subjects must be at least 18 years of age and have a clinical diagnosis of moderate to 
severe psoriasis (defined as an IGA score of 3 or 4). 
Approximately 210 subjects who meet the study entry criteria will be randomized in a 
2:1 ratio to receive IDP-122 (HP 0.01%) Lotion and IDP-122 Vehicle Lotion, respectively. 
The assigned study drug will be applied topically to the affected area (as determined by the 
investigator at Baseline) once daily for 8 weeks. The initial application will be made at the 
investigational center during the day as per instruction from the study coordinator or 
designee. The subjects will be instructed to avoid exposure to direct sunlight, artificial 
ultraviolet light sources and to use protective clothing to prevent sunburn. Subjects will apply 
their daily treatments at home as explained by the study coordinator or designee at each 
investigational center. The study coordinator or designee at each investigational center will 
dispense 2 new containers of study drug to each subject at Baseline and Weeks 2, 4, and 6. 
During post-baseline study visits (Weeks 2, 4, 6, and 8) the subjects will be asked to return 
their used containers of study drug. Subjects will be asked to not apply study drug on day of 
clinic visit so that subject can apply during the visit after assessments are completed. Upon 
completion of the 8-week treatment period, all subjects will be asked to return to the 
investigational center 4 weeks later for a post-treatment cessation follow-up visit (Week 12). 
During the study, each subject will only be permitted to use Investigator approved non-
medicated cleansers, moisturizers and sunscreens; no other skin care products will be 
permitted on the treatment areas. 
The investigator will assess the treatable areas affected by psoriasis at each study visit. All 
treatable areas affected by psoriasis identified at Baseline (with an affected BSA of 3%-12%) 
are to be treated with study drug. The treatable affected areas will not include the face, scalp, 
palms, soles, axillae, and intertriginous areas. If palms and soles are affected, study drug may 
be applied at the discretion of the investigator; however, these areas will not be included in 
treatable BSA or efficacy assessments. 
Information on reported and observed adverse events (AEs) will be obtained at each visit. An 
abbreviated physical examination will be performed at Baseline, Week 8 (end of treatment), 
and Week 12 (the 4-week post-treatment cessation follow-up visit) for all subjects. 
Blood samples for complete blood count with differential (CBC/Diff) and serum chemistry 
will be collected from subjects at Screening, Week 4, and Week 8. For all female subjects of 
childbearing potential, urine and serum pregnancy testing will be performed at Screening and 


Protocol V01-122A-302, IDP-122 Phase 3 
 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
22 
confirmed at baseline with a urine pregnancy test prior to randomization. Serum pregnancy 
tests will also be conducted at weeks 4 and 8, and an additional urine pregnancy test will be 
performed at Week 12 (4-week post-treatment follow-up visit). 
The Dermatology Life Quality Index questionnaire (DLQI) questionnaire will be 
administered to subjects at Day 0 (Baseline), Week 4, Week 8/End of Treatment and Week 
12 (4-week post-treatment follow-up visit). 
Subjects who terminate study participation early will be asked to complete all Week 8 
assessments, as appropriate, prior to commencement of any alternative therapy for psoriasis 
(if possible). Subjects who discontinue from the study during the treatment period will not be 
replaced and these subjects may be asked to come back for the 4-week post-treatment 
cessation follow-up visit. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Version 1, Clinical Study Protocol, 14 July 2015  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL 
23 
Table 1. 
Study Design and Schedule of Assessments 
PROCEDURES 
-Day -35 to 
-1 
Screening
Day 0 
Baseline 
Week 2 
(14 ± 3 days) 
Week 4 
(28 ± 3 days) 
Week 6 
(42 ± 3 days) 
Week 8/ET a
(56 ± 5 days) 
Week 12/FU 
(Day 84 ± 7 
days)
Informed consent 
X 
 
 
 
 
 
 
Demographics 
X 
 
 
 
 
 
 
Medical history b
X 
X 
 
 
 
 
 
Previous psoriasis therapies b
X 
X 
 
 
 
 
 
Inclusion/Exclusion criteria b
X 
X 
 
 
 
 
 
Abbreviated physical examination c 
 
X 
 
 
 
X 
X 
Pregnancy testing d 
X 
X
X
X
X
Clinical laboratory tests e 
X 
X
X
DLQI questionnaire 
 
X 
X
X
X
Investigator’s Global Assessment  
X 
X 
X 
X
X
X
X
Psoriasis Signs Assessment (Target Lesion) 
X 
X 
X 
X
X
X
X
Body surface area (BSA) affected evaluation 
X 
X 
X 
X
X
X
X
Local skin reactions evaluation 
 
X 
X 
X
X
X
X
Randomization 
 
X 
 
 
 
 
 
Review study drug application instructions 
 
X 
X 
X 
X 
Study drug weighed and dispensed 
 
X 
X 
X 
X 
Study drug collected and weighed 
X 
X 
X 
X 
Study diary calendar dispensed 
 
X 
X 
X 
X 
Review compliance with dosing / Diary 
X
X
X
X
Review adverse events 
 
X 
X 
X
X
X
X
Review concomitant therapies 
X 
X 
X 
X
X
X
X
Study exit/end of study form 
X
ET = early termination; FU = follow-up 
a For subjects who discontinue early during the treatment period, all procedures outlined for the ET visit should be completed at the time of discontinuation or within 
2 weeks of discontinuation. 
b Update at  Day 0 (Baseline). 
c Height will be measured at Baseline only; vital signs, weight measurements and examinations of other abbreviated physical parameters will be performed at 
Baseline, Week 8, and Week 12. 
d All female subjects of childbearing potential will undergo serum pregnancy testing at Screening, Week 4, and Week 8. In addition, urine pregnancy testing will be 
performed at Screening, Baseline (prior to randomization), and Week 12 (4-week post-treatment follow-up visit).
e Blood samples for laboratory tests will be collected at Screening prior to study drug application. Clinically significant laboratory findings at Week 4 or Week 8 will 
be repeated at the discretion of the investigator, and the subject will be followed until resolution (return to normal or to the baseline state) or until clinically stable as 
determined by the investigator.


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
24 
8 Selection and Withdrawal of Subjects 
8.1 
Subject Inclusion Criteria 
Subjects meeting all of the following criteria will be eligible for study entry: 
1. Male or female, of any race, at least 18 years of age. 
2. Freely provides both verbal and written informed consent. 
3. Has an area of plaque psoriasis appropriate for topical treatment that covers a (BSA) 
of at least 3%, but no more than 12%. The face, scalp, palms, soles, axillae, and 
intertriginous areas are to be excluded in this calculation. 
4. Has a clinical diagnosis of psoriasis at the Baseline visit with an IGA score of 3 or 4 
(the face, scalp, palms, soles, axillae and intertriginous areas are to be excluded in this 
calculation, if psoriasis is present). 
5.  Has a target lesion that meets the following criteria: 
x Measures between 16-100 cm2 inclusive 
x A score of at least 3 for at least 2 of the 3 different psoriasis signs (erythema, plaque 
elevation, and scaling); with a sum of the three scores at least eight (8) and cannot 
have a score of 0 or 1 on any one of the signs 
x Target lesions cannot be on excluded areas or areas covering bony prominences 
(i.e., elbows and knees) 
6. Is in good general health based on the subject’s medical history and a physical 
examination, with Screening hematology, and serum chemistry laboratory values 
within normal range or not clinically significant as determined by the investigator. 
7. If female and of childbearing potential, must have a negative urine and serum 
pregnancy test at Screening and negative urine pregnancy test at Baseline prior to 
randomization. 
8. If female, is either not of childbearing potential, defined as postmenopausal for at 
least 12 months or surgically sterile (bilateral tubal ligation, bilateral oophorectomy 
or hysterectomy), or is of childbearing potential and practicing 1 of the following 
methods of birth control throughout the study: 
x Condom with spermicide, diaphragm with spermicide, intrauterine device, or 
abstinence 
x Stable use of a hormonal contraceptive (oral, implant, insertable, injection or 
transdermal patch) for at least 3 months prior to the Baseline visit 
9. Subject is willing to comply with study instructions and return to the clinic for 
required visits 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
25 
8.2 
Subject Exclusion Criteria 
Subjects meeting any 1 of the following criteria will be excluded from the study: 
1. Has spontaneously improving or rapidly deteriorating plaque psoriasis or pustular 
psoriasis, as determined by the investigator. 
2. Presents with psoriasis that was treated with prescription medication and failed to 
respond to treatment, even partially or temporarily, as determined by the investigator. 
3. Presents with any concurrent skin condition that could interfere with the evaluation of 
the treatment areas, as determined by the investigator. 
4. Is pregnant, nursing an infant, or planning a pregnancy during the study period. 
5. Has received treatment with any investigational drug or device within 60 days or 
5 drug half-lives (whichever is longer) prior to the Baseline visit, or is concurrently 
participating in another clinical study with an investigational drug or device. 
6. Received treatment with any topical antipsoriatic drug product within 14 days prior to 
the Baseline visit. 
7. Has used any phototherapy (including laser), photochemotherapy, or non-biologic 
systemic psoriasis therapy (such as newer oral psoriasis medications (eg Otezla), 
systemic corticosteroids, methotrexate, retinoids, or cyclosporine) within 4 weeks 
prior to the Baseline visit. 
8. Has used immunomodulatory therapy (biologics) known to affect psoriasis within 
3 months of the Baseline visit. 
9. Has had prolonged exposure to natural or artificial sources of ultraviolet radiation 
within 4 weeks prior to the Screening visit or is intending to have exposure during the 
study thought likely by the investigator to modify the subject’s psoriasis. 
10. Is currently using lithium or Plaquenil. 
11. Has a history of hypersensitivity or allergic reaction to any of the study drug 
constituents. 
12. Is unable to be compliant with study procedures, study drug administration 
requirements, study visit schedules, and prohibitions regarding the use of concomitant 
medications/therapies. 
13. Is unable to communicate or cooperate with the investigator. 
14. Has any underlying disease (eg, uncontrolled diabetes, cardiac disease) that the 
investigator deems uncontrolled that poses a concern for the subject’s safety while 
participating on the study. 
15. Has a history of drug or alcohol abuse. 
16. Is considered by the investigator, for any other reason, to be an unsuitable candidate 
for the study. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
26 
8.3 
Subject Withdrawal Criteria 
Reasons for withdrawal may include, but are not limited to, the following: 
x Psoriasis flare, as determined by the investigator, which requires treatment with a 
disallowed therapy. 
x Either at the investigator's request, for tolerability reasons (e.g., severe adverse 
reactions), or at the subject’s request. 
x When the requirements of the protocol are not followed. 
x When a concomitant therapy likely to interfere with the results of the study is 
reported, or required by the subject (the investigators will report all such 
information on the source documents/electronic case report forms (eCRFs) and 
decide, in accordance with the sponsor, whether the subject is to be withdrawn). 
x When a subject is lost to follow-up. The investigators will try twice to reach the 
subject by telephone and will send a follow-up letter by certified mail before 
considering that the subject is lost to follow-up. These actions will be reported on 
the End of Study eCRF and a copy of the follow-up letter maintained in the 
investigator's file. 
All premature discontinuations and their reasons must be carefully documented by the 
investigator on the final eCRF, and, if need be, on the AE form. In any case, no subject who 
has been included and has a study number assigned can be replaced by another if they 
discontinue prematurely for whatever reason. All data gathered on the subject prior to 
termination will be made available to the sponsor. 
Reasons for study completion/discontinuation as listed on the final report form are defined as 
follows: 
Normal Study Completion – Subject completes the study as planned in the protocol. 
Adverse Event – Complete AE form. 
Subject Request – Consent withdrawal, subject moved, schedule conflicts. 
Protocol Violation – Contact the Sponsor or designee before making decision. 
Lost to Follow-Up – Document with 2 phone calls and a certified letter. 
Pregnancy – Subject will discontinue study drug immediately, but will be followed to 
term. Complete pregnancy form. 
Worsening Condition – Subject requires alternate treatment for psoriasis before the end 
of the study and the investigator determines it is not due to lack of efficacy. 
Lack of Efficacy – Subject requires alternate treatment for psoriasis after at least 2 weeks 
of study drug treatment and the risk of continuing the subject in the study outweighs the 
benefit as determined by the investigator. 
Other – Specify in comments section of final eCRF. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
27 
Subjects who terminate treatment early will be asked to complete all Week 8 assessments 
prior to commencement of any alternative therapy for psoriasis (if possible). Subjects who 
discontinue from the study during the treatment period will not be replaced and these subjects 
will be asked to come back for the 4-week post-treatment cessation follow-up visit. 
All subjects are free to withdraw from participating in this study at any time and for whatever 
reason, specified or unspecified, and without prejudice. No constraints will be placed on 
ordinary subject management, and subjects, when appropriate, will be placed on other 
conventional therapy upon request or whenever clinically necessary as determined by their 
physician.
9 Treatment Plan 
9.1 
Methods of Assigning Subjects to Treatment Groups 
This is a double-blinded study, in which the identity of the study drug will be unknown to 
investigator/evaluator and subjects, as well as all individuals closely associated with the 
study.
Subjects will be randomized to 1 of the 2 study drug groups in a ratio of 2:1 (IDP-122 
[HP 0.01%] Lotion: IDP-122 Vehicle Lotion). Each screened subject will be assigned a 
unique 6-digit study subject number assigned by the investigational center, which will consist 
of the 3-digit investigational center/site number (pre-assigned by sponsor/designee) and the 
3-digit chronological screening order number, starting with 001 (e.g., 101001, 101002). The 
study drug kit will be assigned to subjects based on a randomization code and kits will be 
dispensed to the subjects at Baseline.  A study drug log will document the inventory and 
dispensing of study drug at each investigational center. 
9.2 
Randomization and Blinding 
The study drugs will be packaged and labeled identically, and the study drug kits will be 
numbered sequentially and dispensed randomly to the subjects entering the study within each 
investigational center. Study drug supplies will be distributed to the investigational centers to 
maintain the randomization ratio within each investigational center. 
As a double-blinded study, the investigators, the site staff, the sponsor, and the clinical 
monitors will not be aware of the treatment assigned to the individual study subjects. 
Delegated staff members at each investigational center will dispense the study drugs and will 
collect all used and unused study drug containers as scheduled. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
28 
9.3 
Unblinding
The treatment assignments for all enrolled subjects will be unblinded only after the 
conclusion of the study. Specifically, the blind will be broken only after all data are verified, 
entered into the database, and validated; subject evaluability assessments are performed and 
entered into the database; and the database is locked. 
In the case of a medical emergency, the investigator can break the blind for the subject 
involved preferably by first discussing the situation with the medical monitor and the sponsor 
(or designee) immediately. After confirmation, the investigator will be contacted with 
unblinding information by a sponsor representative. The investigator will record the code 
break in the subject’s source documents. 
9.4 
Prior and Prohibited Concomitant Medication or Therapy 
Subjects in this study must not have psoriasis that was previously nonresponsive to 
prescription medications, per the Investigators’ best clinical judgment. Subjects must also not 
be using lithium or Plaquenil. Any concomitant therapy stopped for washout as indicated 
below is to be recorded. As noted in the exclusion criteria, there are mandatory washout 
periods and restrictions during the study. Specifically: 
x Received treatment with any topical antipsoriatic drug product within 14 days 
prior to the Baseline visit 
x Within 4 weeks prior to the Baseline visit, subjects must not have used any 
phototherapy (including laser), photochemotherapy, or non-biologic systemic 
psoriasis therapy (such as newer oral psoriasis medications (eg Otezla), systemic 
corticosteroids, methotrexate, retinoids or cyclosporine) 
x Has used immunomodulatory therapy (biologics) known to affect psoriasis within 
3 months of the Baseline visit 
x Within 4 weeks prior to the Baseline visit, subjects must not have had prolonged 
exposure to natural or artificial sources of ultraviolet radiation 
x Within 60 days or 5 drug half-lives (whichever is longer) prior to the Baseline 
visit, subjects must not have received treatment with any investigational drug or 
device and may not be concurrently participating in another clinical study with an 
investigational drug or device 
Subjects are allowed only the use of investigator approved non-medicated cleansers, 
moisturizers and sunscreens in the treatment areas. Protocol excluded areas (face, scalp, 
axillae, and intertriginous areas) may be treated with OTC 1% hydrocortisone cream, tar 
shampoos or allowed moisturizers. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
29 
Protocol excluded areas of palms and soles may be treated with study drug but will not be 
included in the BSA or IGA assessments. If palms and soles are treated, they may be 
evaluated by the investigator for improvement. 
Subjects using concomitant therapies during the course of the study that could interfere with 
the interpretation of the study results (including but not limited to those listed above) should 
not be withdrawn, but the use of the concomitant product should be discontinued. No other 
topical treatment (except as noted above) other than the study drug will be permitted for 
psoriasis.
Information on concomitant therapies will be recorded in the Prior and Concomitant 
Medication or Therapy source document. Any therapy used by the subject will be considered 
concomitant medication or therapy (e.g., aspirin, Tylenol, birth control pills, vitamins, 
moisturizers, sunscreens). Every attempt should be made to keep concomitant therapy dosing 
constant during the study. Any change to concomitant therapy should be noted on the 
Concomitant Therapy source document and eCRF. 
9.5 
Treatment Compliance 
Each subject will be instructed on the importance of returning his or her study drug at each 
applicable study visit. If a subject does not return his or her study drug, he or she will be 
instructed to return it as soon as possible. The subjects will bring the containers dispensed at 
each on-site treatment visit to the next subsequent study visit. The maximum allowable 
weekly usage is 50 grams for this study. Each container will be weighed by a study 
coordinator or designee prior to dispensation and after collection. The subject will also be 
asked to complete a diary calendar and questioned regarding the study drug use since the 
previous visit in order to judge the subject’s compliance with applying the study drug. A 
subject who deviates significantly from the prescribed application amount will be counseled. 
Any missed applications of study drug will be noted by subject on the diary, which will be 
collected and placed in the appropriate source document. Missed applications will be 
documented in the eCRF. 
9.6 
Protocol Deviations and Violations 
The investigators must read the protocol thoroughly and must follow the instructions exactly.  
A deviation from the protocol is an unintended and/or unanticipated departure from the 
procedures and/or processes approved by the sponsor and the IRB/IEC and agreed to by the 
investigator. Deviations usually have an impact on individual patients or a small group of 
patients and do not involve inclusion/exclusion or primary endpoint criteria. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
30 
A protocol violation occurs when there is nonadherence to the protocol that results in a 
significant, additional risk to the patient, when the patient or investigator has failed to adhere 
to significant protocol requirements (inclusion/exclusion criteria) and the patient was 
enrolled without prior sponsor approval, or when there is nonadherence to FDA regulations 
and/or ICH GCP guideline. 
The investigator or designee must document and explain in the patients’ source 
documentation any deviation from the approved protocol. The investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study 
patients without prior IRB/IEC approval. As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol 
amendment(s) should be submitted to the IRB/IEC for review and approval, to the sponsor 
for agreement, and to the regulatory authorities, if required. 
10 Study Drug Materials and Management 
The study drug will be dispensed by an appropriately qualified member of the study staff 
assigned by the investigator to this task 
10.1 IDP-122 Lotion and IDP 122 Vehicle Lotion 
The study drug contains the following ingredients: HP, diethyl sebacate, light mineral oil, 
sorbitan monooleate, sorbitol, disodium edetate dihydrate, Pemulen TR-1, Carbopol 981, 
methylparaben, propylparaben, sodium hydroxide, and purified water. 
The vehicle contains the following ingredients: Diethyl sebacate, light mineral oil, sorbitan 
monooleate, sorbitol, disodium edetate dihydrate, Pemulen TR-1, Carbopol 981, 
methylparaben, propylparaben, sodium hydroxide, and purified water. 
10.1.1 Packaging and Labeling 
IDP-122 Lotion and IDP-122 Vehicle Lotion will be packaged in identical study drug kits. 
Each kit will contain 2 containers (tubes), each containing 45 grams of study material. The 
subjects will be dispensed both containers at Baseline as assigned by the IRT system. The 
containers will be weighed prior to dispensing. The subject will bring the containers to the 
next study visit, where they will be collected and weighed; 2 new containers will be 
dispensed again by the IRT system,  weighed and provided to the subject at each on 
treatment study visit. If the subject loses a container (lost or damaged tube), another kit will 
be dispensed via IRT. Each drug container dispensing will be documented on the drug 
accountability log. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
31 
 Labels on the containers will contain the following information: 
x Protocol Number 
x Subject Number 
x Space for entry of the subject initials 
x Space for entry of date dispensed 
x A statement reading, “For external use only. Avoid contact with eyes and lips” 
x A statement reading, “Store at controlled room temperature 20°C to 25°C (68°F to 
77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F)” 
x A statement indicating the sponsor, Dow Pharmaceutical Sciences, a Division of 
Valeant Pharmaceuticals North America LLC 
x A statement indicating the quantity of product (45 grams) 
x A statement reading, “Caution: New Drug Limited by Federal Law to 
Investigational Use” 
x A statement reading, “Keep out of Reach of Children” 
10.1.2 Storage, Handling, and Disposal of Study Drug 
The study drug should be stored at controlled room temperature 20°C to 25°C (68°F to 77°F) 
with excursions permitted between 15°C to 30°C (59°F to 86°F). 
10.1.3 Administration 
The investigational center staff member will instruct the subject on the proper application 
procedure of the study drug to the affected treatment areas identified at the Baseline visit by 
the investigator. Subjects will be instructed to squeeze a small amount of study drug (about 
the size of a pea) onto a fingertip and then spread a thin layer of the study drug over the 
affected treatment area. If necessary, additional pea-sized amounts of study drug may be 
applied in increments to cover all affected treatment areas as designated by the investigator. 
The maximum allowable weekly usage is 50 grams for this study. In addition to the verbal 
instructions given during the visit, the subjects will be provided with written instructions (See 
Appendix 17.1).
Subjects will be instructed to apply a thin layer of study drug to the entire selected treatment 
area(s), as indicated on the body diagram. Subjects will be advised to avoid or minimize 
exposure to direct sunlight and artificial ultraviolet light sources while in the study and to 
wash their hands before and after application of the study drug. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
32 
It is suggested that subjects do not apply study drug on day of clinic visits so that this may be 
done by the subject at the clinic after study assessments are completed and to confirm proper 
application technique and retrain as necessary. 
10.2 Study Drug Accountability 
Upon receipt of the study drug, the investigator is responsible for ensuring that the 
investigational center staff member will conduct a complete inventory of study materials and 
assume responsibility for their storage and dispensing. In accordance with federal 
regulations, the investigators must agree to keep all study materials in a secure location with 
restricted access. The investigator will keep a record of the inventory and dispensing of all 
study drug. This record will be made available to the sponsor’s monitor for the purpose of 
accounting for all clinical supplies. Any significant discrepancy and/or deficiency must be 
recorded with an explanation. 
All supplies sent to the investigators will be accounted for and, in no case, used in any 
unauthorized situation. Each tube will be weighed (with the cap on) before dispensing to and 
upon return by the subjects, and weights will be recorded on the pharmacy log and 
appropriate eCRF. All used and unused supplies will be returned to the sponsor/designee for 
destruction at the conclusion of the study. 
11 Study Procedures and Evaluations 
All subject information and data obtained during the study visits will be recorded in the 
source documents, applicable study logs, and eCRFs. 
Evaluators must have appropriate, documented experience and training, or obtain approval 
from the sponsor based on experience (or through additional training organized by the 
sponsor).
At each study visit, every attempt should be made to ensure that the same 
investigator/evaluator assesses the same subject. 
11.1 Schedule of Evaluations and Procedures 
11.1.1 Screening Visit (Day -35 to Day -1) 
The following procedures will be conducted at this visit: 
1. Obtain verbal and written informed consent from the subject prior to performing any 
study related procedures. Give a signed copy to the subject. 
2. Review and explain the nature of the study. Provide a visit schedule with the length of 
each visit to ensure subject can meet the requirements and has adequate 
transportation. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
33 
3. Assign the subject a 6-digit subject number by accessing IRT, which will consist of 
the 3-digit site number (pre-assigned to your site) and the 3-digit chronological order 
screening number, assigned by the IRT system and starting with 001 (e.g., 101001, 
101002, etc.; in this example site number is 101). 
4. Record the subject’s demographic information. 
5. Record the subject’s medical history. 
6. Record all previous medications for psoriasis used during the past 6 months under 
Prior and Concomitant Medications or Therapies. Include all medications used in the 
past 30 days and any therapy that requires a washout prior to Baseline. 
7. Record any prescription or over-the-counter therapies that are being used 
concomitantly under Prior and Concomitant Medications or Therapies. All 
medications taken within 30 days of the Screening visit should be recorded including 
any that may have ended prior to the Screening visit. 
8. Record all previous cleansers, moisturizers, etc. in the past 30 days under Prior and 
Concomitant Medications or Therapies. Inform subjects that only Investigator-
approved non-medicated cleansers, moisturizers and sunscreens are allowed. 
9. The investigator will assess the BSA affected by psoriasis and determine whether the 
locations of plaques are treatable with the study drug. The face, scalp, palms, soles, 
axillary areas, and other intertriginous areas will not count towards the total treatable 
BSA calculation. 
10. The investigator/evaluator will conduct the IGA for the disease severity of the 
treatment areas. The face, scalp, palms, soles, axillary areas and other intertriginous 
areas will not be included in the severity score using the IGA scale. Every attempt 
should be made for the same sponsor-approved, qualified evaluator to perform the 
evaluations for the same subject. 
11. The investigator/evaluator will select a target lesion measuring between 16-100 cm2
inclusive. Target lesion cannot be on excluded areas or areas covering bony 
prominences (i.e., elbows and knees). 
12. The investigator/evaluator will assess the signs of psoriasis (erythema, plaque 
elevation, and scaling) of the selected target lesion. 
13. For female subjects of childbearing potential collect a urine sample for a urine 
pregnancy test.
14. Verify that the subject meets the applicable inclusion/exclusion criteria as outlined in 
Sections 8.1 and 8.2. 
15. Discuss the use of acceptable cleansers and moisturizers (only products approved by 
the investigator for this study will be allowed) with the subject. 
16. Collect blood samples for routine laboratory analysis (CBC/Diff and serum chemistry 
and for remales subjects of childbearing potential serum pregnancy). 
17. Schedule subject to return for the Baseline/Day 0 visit. If the subject requires a 
washout, schedule the Baseline/Day 0 visit to occur after the washout is complete. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
34 
NOTE: At the Screening, Weeks 4, and 8 visits, serum pregnancy testing is mandatory for 
all females of childbearing potential. In addition, a urine pregnancy test must be completed at 
Screening and at the Baseline visit prior to randomization, and at Week 12. The decision may 
be made by the investigator to do additional pregnancy tests during the course of the study. 
11.1.2 Baseline Visit (Day 0) 
The following procedures will be conducted at this visit: 
1. Record any changes in medical history since Screening. 
2. Record changes in any previous psoriasis medications since the previous visit under 
Prior and Concomitant Medications or Therapies. Check for prohibited concomitant 
therapies and confirm any therapy that requires a washout prior to Baseline as per 
Section 9.4. 
3. Record changes in any concomitant medications since the previous visit under Prior 
and Concomitant Medications or Therapies. Check for prior and concomitant 
therapies as per Section 9.4. 
4. Record changes in cleansers, moisturizers and sunscreens since the previous visit 
under Prior and Concomitant Medications or Therapies. Remind subjects that only 
Investigator-approved non-medicated cleansers, moisturizers and sunscreens are 
allowed. 
5. Verify that the subject continues to meet the applicable inclusion/exclusion criteria as 
outlined in Sections 8.1 and 8.2. 
6. For female subjects of child bearing potential, perform a urine pregnancy test prior to 
randomization. The pregnancy test must be negative for the subject to be eligible for 
randomization. 
7. Provide subject with DLQI for completion. 
8. The investigator will perform an abbreviated physical examination including 
measurements of height, weight, and vital signs (blood pressure, heart rate, 
respiration rate, and oral temperature). 
9. The investigator will determine the extent of psoriasis, i.e., percent of body surface 
area (BSA) involvement in the selected treatment areas. The face, scalp, palms, soles, 
axillary areas, and other intertriginous areas will not count towards the total treatable 
BSA calculation. 
10. The investigator/evaluator will conduct the IGA for the disease severity of the 
treatment area. The face, scalp, palms, soles, axillary areas, and other intertriginous 
areas will not count towards the IGA severity score. Every attempt should be made 
for the same sponsor-approved, qualified evaluator to perform the evaluations for the 
same subject. 
11. The investigator/evaluator will select a target lesion measuring between 16-100 cm2
inclusive. Target lesion cannot be on excluded areas or areas covering bony 
prominences (i.e., elbows and knees).  


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
35 
12. The investigator/evaluator will assess the signs of psoriasis (erythema, plaque 
elevation, and scaling) of the selected target lesion. 
13. The investigator/evaluator will evaluate local skin reactions (itching, dryness, 
burning/stinging, skin atrophy, striae, telangiectasia and folliculitis) by observation 
and questioning the subjects as necessary. 
14. Randomize the subject using the IRT system and record the assigned kit number in 
the source document and in the eCRF. 
15. The study coordinator or designee will weigh each tube within the assigned kit and 
dispense them to the subject. A study diary calendar will also be dispensed. 
16. The study coordinator or designee will instruct the subject on the proper application 
procedure for the study drug. For the first application, the subject will apply the study 
drug at the investigational center during the day under the direction of the study 
coordinator or designee. The study drug should be applied after all clinical 
assessments. The subjects will be asked to avoid exposure to direct sunlight and 
artificial ultraviolet light sources on the initial application day and thereafter. The 
study coordinator or designee will instruct the subjects to apply the study drug once 
daily at home. 
17. Record any AEs reported spontaneously by the subject. 
18. Schedule the next study visit at Week 2 (Day 14 ± 3 days). 
11.1.3 Week 2 (Day 14 ± 3 Days), Week 4 (Day 28 ± 3 Days), Week 6 (Day 42 ± 3 Days) 
Visits
The following procedures will be conducted at this visit: 
1. Record changes in any concomitant medications since the previous visit under Prior 
and Concomitant Medications or Therapies. Check for prior and concomitant 
therapies as per Section 9.4. 
2. Record changes in cleansers, moisturizers and sunscreens since the previous visit 
under Prior and Concomitant Medications or Therapies. Remind subjects that only 
investigator approved non-medicated cleansers, moisturizers and sunscreens are 
allowed. 
3. Record any new AEs reported spontaneously by the subject or changes in any 
ongoing AEs. 
4. The investigator will determine the percent BSA affected by Psoriasis. 
5. The investigator/evaluator will conduct the IGA for the disease severity of the 
treatment area. The face, scalp, palms, soles, axillary areas, and other intertriginous 
areas will not count towards the IGA severity score. Every attempt should be made 
for the same sponsor-approved, qualified evaluator to perform the evaluations for the 
same subject. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
36 
6. The investigator/evaluator will assess the signs of psoriasis (erythema, plaque 
elevation, and scaling) on the selected Target Lesion 
7. The investigator/evaluator will evaluate local skin reactions (itching, dryness, 
burning/stinging, skin atrophy, striae, telangiectasia and folliculitis) by observation 
and questioning the subjects as necessary. 
8. At Week 4, collect blood samples for routine laboratory analysis (CBC/Diff, serum 
chemistry, and for women of child bearing potential a serum pregnancy test). 
9. At Week 4, provide subject with DLQI for completion. 
10. The study coordinator or designee will collect and weigh the previously dispensed 
study drug tubes. The study coordinator or designee will weigh and dispense 2 new 
study drug tubes from the next IRT-assigned kit to the subject. 
11. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. A new study diary calendar will be dispensed. 
12. The study coordinator or designee will remind the subject of the proper technique for 
application of the study drug. Preferably, the subject can apply the study drug at the 
investigational center during the day under the direction of the study coordinator or 
designee to confirm proper technique.  Any necessary retraining can be completed.  
The study drug should be applied after all clinical assessments. 
13. Schedule the subsequent study visit, as applicable. 
11.1.4 Week 8 (Day 56 ± 5 Days) End of Treatment – Perform these Visit Procedures 
for Subjects who Discontinue Treatment Early 
The following procedures will be conducted at this visit: 
1. Record changes in any concomitant medications since the previous visit under Prior 
and Concomitant Medications or Therapies. Check for prior and concomitant 
therapies as per Section 9.4. 
2. Record changes in cleansers, moisturizers and sunscreens since the previous visit 
under Prior and Concomitant Medications or Therapies. Remind subjects that only 
investigator approved non-medicated cleansers, moisturizers and sunscreens are 
allowed. 
3. Record any new AEs reported spontaneously by the subject or changes in any 
ongoing AEs. 
4. 4. The investigator will determine the percent BSA affected by Psoriasis. 
5. The investigator/evaluator will conduct the IGA for the disease severity of the 
treatment area. The face, scalp, palms, soles, axillary areas, and other intertriginous 
areas will not count towards the IGA severity score. Every attempt should be made 
for the same sponsor-approved, qualified evaluator to perform the evaluations for the 
same subject. 
6. The investigator/evaluator will assess the signs of psoriasis (erythema, plaque 
elevation, and scaling) on the selected Target Lesion 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
37 
7. The investigator/evaluator will evaluate local skin reactions (itching, dryness, 
burning/stinging, skin atrophy, striae, telangiectasia and folliculitis) by observation 
and questioning the subjects as necessary. 
8. The investigator will perform an abbreviated physical examination including 
measurements of weight and vital signs (blood pressure, heart rate, respiration rate, 
and oral temperature). 
9. Collect blood samples for routine laboratory analysis (CBC/Diff and serum 
chemistry). 
10. For women of child bearing potential, collect a blood sample for a serum pregnancy 
test. 
11. Provide subject with DLQI for completion. 
12. The study coordinator or designee will collect all previously dispensed study drug 
tubes (used and unused) and weigh all collected tubes. 
13. The study diary calendar will be collected and reviewed for compliance. Any missed 
doses or deviations should be reported. 
14. Schedule the 4-week post-treatment follow-up visit to occur on Day 84 (± 7 days). 
Note: For subjects who exit the study prior to completing Week 8, perform all of the 
assessments scheduled for Week 8 at the time that the subject discontinues or within 
2 weeks of subject discontinuation. The subject will be asked to come back for the 
4-week post-treatment cessation follow-up visit. 
11.1.5 Week 12 (Day 84 ± 7 Days) – 4-Week Post-Treatment Cessation Follow-Up Visit 
The following procedures will be conducted at this visit: 
1. Record changes in any concomitant medications since the previous visit under Prior 
and Concomitant Medications or Therapies. Check for prior and concomitant 
therapies as per Section 9.4. 
2. Record changes in cleansers, moisturizers and sunscreens since the previous visit 
under Prior and Concomitant Medications or Therapies. Remind subjects that only 
investigator approved non-medicated cleansers, moisturizers and sunscreens are 
allowed. 
3. Record any new AEs reported spontaneously by the subject or changes in any 
ongoing AEs. 
4. The investigator will determine the percent BSA affected by Psoriasis. 
5. The investigator/evaluator will conduct the IGA for the disease severity of the 
treatment area. The face, scalp, palms, soles, axillary areas, and other intertriginous 
areas will not count towards the severity score using the IGA scale. Every attempt 
should be made for the same sponsor-approved, qualified evaluator to perform the 
evaluations for the same subject. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
38 
6. The investigator/evaluator will assess the signs of psoriasis (erythema, plaque 
elevation, and scaling) on the selected Target Lesion. 
7. The investigator/evaluator will evaluate local skin reactions (itching, dryness, 
burning/stinging, skin atrophy, striae, telangiectasia and folliculitis) by observation 
and questioning the subjects as necessary. 
8. The investigator will perform an abbreviated physical examination including 
measurements of weight and vital signs (blood pressure, heart rate, respiration rate, 
and oral temperature). 
9. For women of child bearing potential, perform a urine pregnancy test. 
10. Provide subject with DLQI for completion. 
11. Exit the subject from the study and complete the end of study eCRFs. 
Note: For subjects, who exit the study after Week 8 but prior to completing Week 12, 
perform all of the assessments scheduled for Week 12 at the time that the subject 
discontinues or within 2 weeks of subject discontinuation. 
11.2 Evaluation of Efficacy 
11.2.1 Body Surface Area Affected by Psoriasis (BSA) 
The investigator will assess the percent BSA (3%-12% required to qualify at Baseline) 
affected by psoriasis in the allowed treatment areas for each subject at Screening/Baseline 
and at all study visits. The BSA will not include areas of the face, scalp, palms, soles, axillae, 
and other intertriginous areas. Note: palms and soles with psoriasis may be treated with the 
study drug but will not be included in the BSA or IGA assessments. 
11.2.2 Investigator’s Global Assessment (IGA) 
The IGA is based on a 5-point scale ranging from 0 (clear) to 4 (severe), and will be assessed 
by the evaluator at each visit for the overall affected areas with plaque psoriasis. The face, 
scalp, palms, soles, axillae, and intertriginous areas are to be excluded in this assessment. 
The scores to be used to describe the severity of overall psoriasis of the treatable areas are 
shown in Table 2. 
Table 2. 
Investigator’s Global Assessment Scale 
Grade 
Score 
Description  
Clear 
0 
No evidence of scaling; 
No evidence of erythema;  
No evidence of plaque elevation above normal skin level 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
39 
Almost 
Clear
1 
Some plaques with fine scales; 
Faint pink/light red erythema on most plaques; 
Slight or barely perceptible elevation of plaques above normal skin 
level
Mild 
2 
Most to all plaques have some fine scales but are not fully covered, 
some plaques are completely covered with fine scale; 
Most to all plaques are pink/light red to bright red in color; 
Some plaques have definite elevation above normal skin level, 
typically with edges that are indistinct and sloped on some of the 
plaques
Moderate 
3 
Some plaques are at least partially covered with a coarse scale, most 
to all plaques are nearly covered with fine or course scale; 
Most to all plaques are bright red, some plaque may be dark red in 
color;
Definite elevation of most to all plaques; rounded or sloped edges on 
most of the plaques 
Severe 
4 
Most to all plaques are covered with coarse, thick scales; 
Most or all plaques are bright, dark or dusky red; 
Almost all plaques are raised and well-demarcated; sharp edges on 
virtually all plaques
11.2.3 Psoriasis Signs 
The signs of psoriasis (erythema, plaque elevation, and scaling) will be assessed using the 
following scales for the selected target lesion shown in Table 3. 
Table 3. 
Psoriasis Signs 
Score  Grade  
Description 
Erythema: 
0 
None 
No erythema  
1 
Minimum 
Pink discoloration, minimal erythema 
2 
Mild 
Most plaques are light red to red in color 
3 
Moderate 
Most or all plaques are bright red or dark red in color 
4 
Severe 
Most plaques dusky red with purple hue 
Plaque Elevation: 
0 
None 
No evidence elevation above the normal skin level 
1 
Minimum 
Slight, just discernible elevation above normal skin level 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
40 
2 
Mild 
Some plaques show definite elevation with indistinct edges 
3 
Moderate 
Most plaques have definite elevation with distinct edges that 
are rounded or sloped 
4 
Severe 
Almost all plaques are raised above normal skin level with 
sharp edges 
Scaling: 
0 
None 
No scales on very few plaques 
1 
Minimum 
Occasional fine scales hardly noticeable 
2 
Mild 
Most plaques have fine scales 
3 
Moderate 
Some plaques have coarse scales while most plaques have 
fine scales 
4 
Severe 
Most plaques are covered by thick coarse scales 
11.3 Evaluation of Safety 
11.3.1 Localized Skin Reactions 
Tolerability will be evaluated through assessments of selected local signs and symptoms 
(itching, dryness, and burning /stinging). In addition, the treatment areas will be examined by 
the evaluator at each visit for presence or absence of significant known drug-related AEs; 
skin atrophy, striae, telangiectasia, and folliculitis. Any local skin reaction requiring use of a 
concomitant therapy or is a cause for study drug interruption or discontinuation should be 
reported as an adverse event. The scales to be used for assessing local skin reactions are 
shown in
Table 4. 
Localized Skin Reaction Scales 
Score  Grade  
Description 
Itching: as reported by the subject within the last 24 hours 
0 
None 
No itching 
1 
Mild 
Slight itching, not really bothersome 
2 
Moderate 
Definite itching that is somewhat bothersome 
3 
Severe 
Intense itching that may interrupt daily activities and/or sleep 
Dryness: as assessed by the investigator 
0 
None 
No dryness 
1 
Mild 
Slight, but definite roughness 
2 
Moderate 
Definite roughness 
3 
Severe 
Marked roughness 
Burning:/Stinging: as reported by the subject within the last 24 hours 
0 
None 
No burning/stinging  


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
41 
1 
Mild 
Slight burning sensation; not really bothersome 
2 
Moderate 
Definite warm, burning that is somewhat bothersome 
3 
Severe 
Hot burning sensation that causes definite discomfort and may interrupt 
daily activities and/or sleep 
All of the below will be assessed by the investigator as present or absent. 
Skin Atrophy: 
No
Skin atrophy not present
Yes 
Skin atrophy present
Striae: 
No
Striae not present 
Yes 
Striae present 
Telangiectasias: 
No
Telangiectasias not present 
Yes 
Telangiectasias present 
Folliculitis:
No
Folliculitis not present 
Yes 
Folliculitis present 
11.3.2 Medical History and Abbreviated Physical Examination 
A medical history will be taken at Screening, and confirmed and revised if needed, at 
Baseline. Medical histories having resolved 2 or more years before Baseline need not be 
collected unless considered relevant by the investigator. 
An abbreviated physical examination including measurements of weight and vital signs 
(blood pressure, heart rate, respiration rate, and oral temperature) will be performed at 
Baseline, Week 8, and Week 12 (post-treatment follow-up visit). Height will be measured at 
Baseline only.  Any abnormal physical exam findings will be recorded. 
11.3.3 Safety Laboratory Tests 
Routine safety laboratory tests (CBC/Diff and serum chemistry) will be performed at 
Screening, Week 4, and Week 8. Any out-of-range laboratory result that is considered 
clinically significant by the investigator will be recorded as an AE and should be confirmed 
by repeat testing at the discretion of the investigator. Clinically significant laboratory 
abnormalities at any visit will be followed to resolution (return to normal or to the baseline 
state) or until clinically stable as determined by the investigator. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
42 
11.3.4 Pregnancy Tests 
All female subjects of childbearing potential will undergo serum pregnancy testing at 
Screening, Week 4, and Week 8. In addition, urine pregnancy testing will be performed at 
Screening and prior to randomization at Baseline, and at Week 12 (4-week post-treatment 
follow-up visit). 
11.4 Other Evaluations 
11.4.1 Dermatology Life Quality Index (DLQI) 
The DLQI questionnaire will be administered to subjects at Day 0 (Baseline), Week 4, Week 
8/End of Treatment and Week 12 (4-week post-treatment follow-up visit). 
11.5 Adverse Events 
11.5.1 Definition of Adverse Event 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a medicinal product and which does not necessarily have a causal relationship 
with the study drug. AEs include any unfavorable and unintended illness, sign, symptom, 
clinically significant laboratory test abnormality, or disease temporally associated with the 
use of a medicinal product that has appeared or worsened during the course of the clinical 
trial, regardless of causal relationship to the study drug(s) under study. The collection of 
nonserious AEs and serious adverse events (SAEs) should begin following the subject's 
completion of the consent process to participate in the study. 
11.5.2 Documenting Adverse Experiences 
It is the responsibility of the investigator to document all AEs that occur during the course of 
the study. The AEs should be documented as a single medical diagnosis. When this is not 
possible, the AE should be documented in terms of signs and/or symptoms observed by the 
investigator or reported by the subject at each study visit. 
All AEs occurring after the subject signs the informed consent through the last study visit 
must be reported, regardless of whether or not the AEs are considered drug-related. All AEs, 
whether in response to a query, observed by the study site personnel, or reported 
spontaneously by the subject, will be recorded. 
At each visit during the study, the subject will be assessed for the occurrence of new and 
ongoing AEs. Cutaneous tolerability signs and symptoms that result in the subject’s requiring 
a concomitant therapy or discontinuation from the study will be reported as an AE. The 
following data will be collected on all AEs and recorded on the appropriate eCRF: 
x Event name (diagnosis preferred, if unknown, record the signs/symptoms) 
x Onset date and end date 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
43 
x Maximum intensity (severity) 
x Seriousness
x Action taken regarding study drug 
x Corrective treatment, if given 
x Outcome 
In addition, the investigator’s assessment of causality will be recorded. 
Vital sign abnormalities are to be recorded as AEs only if they are clinically significant (for 
example: are symptomatic, requiring corrective treatment, leading to discontinuation or 
fulfilling a seriousness criterion). 
11.5.3 Serious Adverse Events 
All AEs will be assessed as either serious or nonserious. 
An SAE or serious adverse reaction is defined as any untoward medical occurrence that at 
any dose: 
x Results in death 
x Is immediately life threatening, (the term "life threatening" in the definition of 
"serious" refers to an event in which the subject is at risk of death at the time of 
the event; it does not refer to an event which hypothetically might have caused 
death if it were more severe) 
x Requires in patient hospitalization or prolongation of existing hospitalization 
(hospitalization for elective surgery for a baseline condition is not considered an 
AE)
x Results in persistent or significant disability/incapacity (permanent or substantial 
disruption of a person’s ability to conduct normal life functions) 
x Is a congenital anomaly/birth defect 
x Is a medically important event that may not be immediately life threatening or 
result in death or hospitalization, but may jeopardize the subject and may require 
medical or surgical intervention to prevent 1 of the above listed outcomes 
Note: A spontaneous abortion will be considered an SAE, and must be reported to the 
sponsor/designee within 24 hours of your awareness of the event.


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
44 
11.5.4 Assessment of Severity 
The severity assigned to an AE should be determined by the maximum severity of the AE. 
The categories described below should be used to estimate the severity of AEs: 
x Mild: Transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required 
x Moderate: Mild to moderate limitation in activity; some assistance may be 
needed; no or minimal medical intervention/therapy required 
x Severe: Marked limitation in activity; some assistance usually required; medical 
intervention/therapy required; hospitalization or prolongation of current 
hospitalization possible; may be incapacitating or life threatening 
11.5.5 Assessment of Causality 
The investigator should assess the relationship of the AE, if any, to the study drug as either 
“Related” or “Not Related”. The following should be taken into account when assessing SAE 
causality: 
x Positive temporal relationship to study drug, such as if the study drug was 
withdrawn and the SAE resolved or the event recurred after re introduction. 
x If there is a reasonable possibility that the AE is associated with an underlying or 
concomitant illness. 
x Possible association with previous or concomitant therapy. 
x No temporal relationship to the study drug and/or a more likely alternative 
etiology exists. 
x If the AE is directly related to study procedures or there is a lack of efficacy. 
11.5.6 Reporting of Serious Adverse Events 
Adverse events classified as “serious” require expeditious handling and reporting to sponsor 
or designee within 24 hours of investigational center notification to comply with regulatory 
requirements. 
All SAEs, whether related or unrelated to study drug, must be immediately reported to the 
medical monitor within 24 hours of the investigator’s awareness of the event. All SAEs must 
be reported via confirmed facsimile transmission and must be submitted on a written SAE 
report form signed by the investigator within 24 hours of the investigator’s awareness of the 
event. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
45 
The fax number for reporting an SAE is: 
 
 
       
 
 
 
 
Investigators should not wait to receive additional information to fully document the event 
before notifying Medical Monitor of an SAE. If only limited information is initially 
available, follow-up reports are required. Additional relevant information such as hospital 
records and autopsy reports should be provided to Sponsor/designee as soon as they are 
available. Should the investigator become aware of an SAE (regardless of its relationship to 
investigational product) that occurs within 30 days after stopping the study drug, the SAE 
must be reported in accordance with procedures specified in this protocol. 
The investigator should take all appropriate measures to ensure the safety of the subjects, 
notably he/she should follow a subject with an SAE until the event has resolved or the 
condition has stabilized. This may imply that follow-up will continue after the subject has 
left the study, and that additional investigations may be requested by the sponsor. 
11.5.7 Expedited Serious Adverse Event Reports 
An AE, whether serious or nonserious, is designated unexpected (unlabeled) if it is not 
reported in the clinical safety section of the Investigator Brochure or if the event is of greater 
frequency, specificity or severity. 
Expedited SAE reports are those that are both unexpected based on the reference document 
(Investigator Brochure or Package Insert) and are related (i.e., the relationship cannot be 
ruled out) to the study drug. These expedited reports are subject to reporting timelines of 7 
and/or 15 calendar days to the regulatory reporting agency(ies). Valeant Pharmaceuticals will 
notify regulatory authorities of these AEs and all participating investigational centers in 
writing for submission by the investigator to the IRB/IEC. This notification will be in the 
form of a Safety Update to the Investigator Brochure (i.e., “15-day letter”). 
Upon receiving such notices, the investigator must review and retain the notice with the 
Investigator Brochure and immediately submit a copy of this information to the responsible 
IRB/IEC according to local regulations. The investigator and IRB/IEC will determine if the 
informed consent requires revision. The investigator should also comply with the IRB/IEC 
procedures for reporting any other safety information. 
11.5.8 Laboratory Test Abnormalities 
If an AE should require laboratory testing in addition to that required by protocol, the results 
of the test(s) must be obtained by the investigational center and filed with the subject’s 
source documentation. Any laboratory test result that meets the criteria for an SAE must also 
be reported to the sponsor/designee via written SAE report form signed by the investigator 
within 24 hours of investigational center notification. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
46 
11.5.9 Pregnancy
All female subjects of childbearing potential must use an effective method of birth control 
during the course of the study, in a manner such that risk of contraceptive failure is 
minimized. Abstinence is allowed as a birth control method. 
Before enrolling a female subject of childbearing potential in this clinical trial, the 
investigator must review the following information about study participation: 
x Informed consent requirements 
x Contraceptives in current use 
Following review of this information and appropriate subject counseling, the investigator or 
designee and the subject must sign the informed consent before study enrollment. 
During the study, all female subjects of childbearing potential should be instructed to contact 
the investigator immediately if they suspect they might be pregnant (e.g., missed or late 
menstrual period). 
If a subject or investigator suspects that the subject may be pregnant prior to study 
enrollment, the study drug must be withheld until the results of laboratory pregnancy testing 
are available. If pregnancy is confirmed, the subject must not receive study drug and must 
not be enrolled in the study. If pregnancy is suspected while the subject is receiving study 
treatment, the study drug must immediately be withheld until the result of pregnancy testing 
is known. If pregnancy is confirmed, the study drug will be permanently discontinued and the 
subject will be followed until the pregnancy comes to term. A Pregnancy Report form will be 
submitted to the sponsor, initially and at the end of the pregnancy, which includes the 
outcome of the pregnancy and any complications occurring during the pregnancy or the 
delivery.
All confirmed pregnancies must be immediately reported to the medical monitor within 24 
hours of the investigator’s awareness of the pregnancy. All confirmed pregnancies must be 
reported via confirmed facsimile transmission and must be submitted on a written Pregnancy 
Report form within 24 hours of the investigator’s awareness of the pregnancy. 
12 Statistics
All statistical processing will be performed using SAS® unless otherwise stated. No interim 
analyses are planned. Except where noted, all statistical tests will be two-sided and will be 
performed at the 0.05 level of significance. 
Descriptive statistics will be used to provide an overview of the efficacy and safety results. 
For categorical parameters, the number and percentage of subjects in each category will be 
presented. For continuous parameters, descriptive statistics will include n (number of 
subjects), mean, standard deviation, median, minimum, and maximum. Appropriate 
inferential statistics will be used for the primary and secondary efficacy variables. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
47 
The primary method of handling missing efficacy data will be the method of Markov Chain 
Monte Carlo (MCMC) multiple imputation. As a sensitivity analysis, the last observation 
carried forward method (LOCF) will be used (i.e., the last available on-therapy observation 
for a subject will be used to estimate subsequent missing data points). No imputations will be 
made for missing safety data. 
A statistical analysis plan (SAP), describing all statistical analyses will be provided as a 
separate document. The SAP will be finalized prior to unblinding of the study treatments. 
12.1 Assessment of Efficacy 
The primary efficacy endpoint will be the percent of subjects with treatment success, defined 
as at least a 2-grade improvement from Baseline in IGA score and an IGA score equating to 
“Clear” or “Almost Clear”. 
12.1.1 Primary Efficacy 
The primary efficacy endpoint will be used to compare once daily application of IDP-122 
Lotion and vehicle.
The percent of subjects with treatment success at Week 8 will be analyzed using Cochran-
Mantel-Haenszel (CMH) tests stratified by analysis center. 
12.1.2 Secondary Efficacy 
Similar to the primary endpoint analyses comparisons will be performed using CMH tests 
stratified by analysis center. The secondary efficacy endpoints will be: 
x Percentage of subjects who show at least a 2 grade improvement and reach Clear 
to Almost Clear at Week 12 for IDP-122 Lotion verses IDP-122 Vehicle Lotion 
x Percentage of subjects who show at least a 2 grade improvement and reach Clear 
to Almost Clear at Week 6 for IDP-122 Lotion verses IDP-122 Vehicle Lotion 
x Percentage of subjects who show at least a 2 grade improvement and reach Clear 
to Almost Clear at Week 4 for IDP-122 Lotion verses IDP-122 Vehicle Lotion 
x Percentage of subjects who show at least a 2 grade improvement and reach Clear 
to Almost Clear at Week 2 for IDP-122 Lotion verses IDP-122 Vehicle Lotion 
Evaluation of the secondary efficacy variables will use a gated sequential procedure starting 
with the comparisons of the first bulleted item and proceeding onto the next item. The 
process will terminate if a nonstatistically significant value is observed. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
48 
12.1.3 Tertiary Efficacy 
The follow tertiary efficacy endpoints will be analyzed to further characterize the treatment 
effect of IDP-122 Lotion over the IDP-122 Vehicle Lotion. The analyses will use CMH 
testing stratified by analysis center without adjusting for multiplicity. 
x Percentage of subjects with at least a 2-grade improvement from Baseline in the score 
for each of the signs of psoriasis (erythema, plaque elevation, and scaling) at Week 8 
for the target lesion 
x Percentage of subjects with at least a 2-grade improvement from Baseline in the score 
for each of the signs of psoriasis (erythema, plaque elevation, and scaling) at Week 12 
for the target lesion 
x Percentage of subjects with at least a 2-grade improvement from Baseline in the score 
for each of the signs of psoriasis (erythema, plaque elevation, and scaling) at Week 6 
for the target lesion 
x Percentage of subjects with at least a 2-grade improvement from Baseline in the score 
for each of the signs of psoriasis (erythema, plaque elevation, and scaling) at Week 4 
for the target lesion 
x Percentage of subjects with at least a 2-grade improvement from Baseline in the score 
for each of the signs of psoriasis (erythema, plaque elevation, and scaling) at Week 2 
for the target lesion 
12.1.4 Pooling Analysis 
The clinical study will be conducted under a common protocol for each investigational site 
with the intention of pooling the data for analysis. Every effort will be made to promote 
consistency in study execution at each study site. The study is intended to be conducted in a 
manner such that a minimum of 15 subjects will be randomized and included in the ITT 
population (i.e., approximately at least 10 subjects in the IDP-122 arm and at least 5 subjects 
in the Vehicle arm) for any investigator. In the event that there are too few subjects in a 
treatment arm for an investigator, then the investigator’s data will be combined to achieve the 
desired sample size minimum per treatment arm. The combining of investigator data will be 
accomplished by taking the investigator with the smallest enrollment and combining it with 
the investigator with the largest, restricted to investigational sites that did not meet minimum 
enrollment. If there is a further need to combine data, then the data of the investigator with 
the second smallest enrollment will be combined with the investigator's data which had the 
second largest enrollment, and so on. This process will continue for all investigators who did 
not have a minimum of 15 subjects enrolled.


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
49 
The process of combining investigator data that have insufficient subjects per treatment arm 
will result in redefining the groups of investigators for the purposes of statistical analyses. 
These combined groups will be referred to as "analysis centers" in the statistical analyses. 
The consistency of treatment response will be investigated across the analysis centers 
subsequent to combining the data as described above. Statistical tests will be conducted to 
identify if there are extreme analysis centers that could affect the interpretation of common 
statistical and clinical conclusions. For the purpose of testing consistency of treatment 
response, the primary efficacy variable will be considered. The percent of subjects with 
treatment success at Week 8 will be analyzed with a logistic regression with factors of 
treatment group, analysis center, and the interaction term of treatment group by analysis 
center. Further examination will follow if the analysis results in a significant interaction term. 
In the event that the logistic regression interaction p-value is less than or equal to 0.10, a 
sensitivity analysis that excludes analysis centers with the extreme efficacy result will be 
performed to determine the robustness of the treatment effect. On the other hand, if the 
analysis results in an interaction terms with p-value greater than 0.10, then the conclusions 
from the pooled data will be considered to be free of the impact of extreme analysis centers. 
The first step in conducting a sensitivity analysis is to identify the extreme analysis center or 
centers that contribute to the statistical significance of the interaction term of the logistic 
regression. The process involves submitting subsets of analysis centers to the logistic 
regression and observing the interaction p-value for the subset. Subsets resulting in 
interaction p-values greater than 0.10 are considered homogeneous. 
The search for an extreme analysis center begins by analyzing all subsets that can be created 
by excluding 1 analysis center. If 1 or more of the subsets result in an interaction p-value 
greater than or equal to 0.10, then the analysis center excluded from the subset with the 
largest interaction p-value is deemed the extreme analysis center. 
If all subset interaction p-values are less than or equal to 0.10, then the process will analyze 
the interaction for all subsets that can be created by excluding 2 analysis centers. If 1 or more 
of these subsets generate interaction p-values larger than 0.10, then the analysis centers 
excluded from the subset with the largest interaction p-value are deemed the extreme analysis 
centers. 
Thus, the process of identifying the extreme analysis centers will continue in a stepwise 
manner by first excluding 1, then 2, then 3, etc, analysis centers until the logistic regression 
interaction p-value exceeds 0.10. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
50 
Once the extreme analysis center or centers have been identified, then the treatment p-values 
of the remaining analysis centers will be computed. Inferences will be drawn from the 
treatment p-value, as well as any pertinent observations regarding the extreme analysis center 
or centers. Additionally, it is noted that this process excludes subjects from the analysis in a 
nonrandom manner and has an unpredictable impact on the power of the treatment effect test. 
In the event that the treatment effect of the remaining subset is not statistically significant, 
due consideration of the post hoc aspects of the process will be given when the results are 
interpreted. Conclusions will be presented by the sponsor as appropriate to the findings of the 
sensitivity analysis. 
Prior to investigating the treatment effect within the analysis centers, the magnitude of the 
site main effect will be investigated to determine if the main site-to-site variability is such 
that it could mask the analysis center effects. Thus, prior to pooling, the percent of subjects 
with treatment success at Week 8 will be analyzed with a logistic regression with factors of 
treatment group, site, and the interaction term of treatment group by site. If the analysis is not 
computationally feasible due to some sites having very few subjects enrolled, the 
low-enrolling sites will be excluded from the analysis. 
12.1.5 Missing Efficacy Data Imputations 
The primary method of handling missing efficacy data will be MCMC multiple imputation. 
This method does not rely on the assumption of data missing at random. Additionally, 
imputation will be conducted within each treatment group independently, so the pattern of 
missing observations in 1 treatment group cannot influence missing value estimations in 
another.
For each efficacy variable (IGA and psoriasis signs), the following steps will be performed to 
impute missing data: 
1. Calculate the number of missing Week 8 values to be estimated by MCMC in each 
treatment group. Let nmiss be the maximum number of missing Week 8 values 
among the treatment groups. 
2. For each treatment group, create a data set containing subjects with observed values 
and those needing estimation by MCMC. The missing efficacy data in each data set 
will be filled in using the MCMC method ‘5 x nmiss’ times to generate ‘5 x nmiss’ 
data sets. The resulting data set for each treatment group will be combined into 
1 complete data set for each imputation. Options will be included in each imputation 
process to prevent estimating values to be outside the range of expected values for the 
assessment. 
3. Imputed data will be used to determine dichotomized success/failure values. 
4. Each complete data set will be analyzed with the appropriate CMH test. 
5. CMH statistics will be normalized using the Wilson-Hilferty transformation. 
6. The results from these analyses will be combined into a single inference using SAS 
PROC MIANALYZE. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
51 
12.1.6 Sensitivity Efficacy Analyses 
12.1.6.1 Analyses Using Last Observation Carried Forward 
In the first set of sensitivity analyses, missing IGA values will be imputed using LOCF. 
Treatment success at Week 8 will be analyzed as it was in the primary analyses. Comparisons 
will be performed on imputed data using CMH tests stratified by analysis center. 
12.1.6.2 Repeated Measures Analysis on Observed Data 
As a second sensitivity analysis, treatment success at Week 8 will be analyzed with a 
repeated measures logistic regression model (generalized estimating equations), with 
treatment success as the dependent variable and treatment, analysis center and visit 
(Weeks 2, 4, 6 and 8) as independent factors. 
12.1.7 Subgroup Analyses 
Subgroup analyses will be conducted for the ITT population for the following subgroups: 
Baseline IGA, sex, age, ethnicity, and race. Age will be dichotomized to less than the median 
age of subjects and greater than or equal to the median age of subjects. Subgroup analyses 
will be conducted on the primary efficacy endpoint and will contain only descriptive 
statistics. 
12.2 Assessment of Safety 
12.2.1 Adverse Events 
The primary analysis of safety will be conducted at Week 8.  There will be a tabulation, 
however, of the AE’s that start in the period post the Week 8 to Week 12 visit.  All AEs 
occurring during the study will be recorded and classified using terminology from the 
Medical Dictionary for Regulatory Activities (MedDRA). All reported treatment-emergent 
adverse events (TEAEs), defined as any AE with an onset on or after the date of first study 
drug application, will be summarized by treatment group and will provide the number of 
subjects reporting TEAEs, system organ class, preferred term, severity, and relationship to 
study drug. When summarizing TEAEs by severity or relationship to study drug, each subject 
will be counted only once within a system organ class or a preferred term using the event 
with the greatest severity or causality, respectively, within each category. All reported SAEs 
will be summarized by the number of subjects reporting the event, system organ class, 
preferred term, severity, and relationship to study drug. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
52 
All information pertaining to AEs noted during the study will be listed by treatment group 
and subject and will include a verbatim description of the event as reported by the 
investigator, as well as the preferred term, system organ class, start date, stop date (if 
stopped), seriousness, severity, action taken regarding the study drug, corrective treatment, 
outcome, and relationship to the study drug.  
In addition, a listing of subjects who prematurely discontinue from the study due to AEs will 
be provided as well as a listing of subjects who reported an SAE. 
12.2.2 Local Skin Reactions 
The frequency of local skin reactions including itching, dryness, burning/stinging, skin 
atrophy, striae, telangiectasia and folliculitis will be summarized by treatment group and 
visit. Additionally, the percent of subjects who experience a local skin reaction (itching, 
dryness, burning/stinging) graded at a level of 3, at any point in the study following the first 
application of study drug, will be tabulated by treatment group. 
12.2.3 Safety Laboratory Values and Vital Sign Measurements 
Changes from Baseline in safety laboratory values and vital sign measurements will be 
summarized with descriptive statistics for each treatment group at all applicable study visits. 
Shift tables will be presented for changes in safety laboratory values to summarize laboratory 
test results collected at Baseline and Weeks 4 and 8. Normal ranges established by the central 
laboratory will be used to determine the shifts. A listing of all out-of-range laboratory test 
results at any assessment time point will also be provided. Determination of clinical 
significance for all out-of-range laboratory values will be made by each investigator and 
included in the listing. In addition, a listing of all clinically significant laboratory test results 
will be provided. 
12.3 Subject Disposition 
A tabulation of subject disposition will be provided. The tabulation will include the numbers 
of subjects who enter the study, complete the study, and discontinue the study. The reasons 
for discontinuation will be included. 
12.4 Demographics and Baseline Characteristics 
Subject demographic data and Baseline characteristics will be summarized by treatment 
group using descriptive statistics for the ITT, PP, and safety analysis sets. Comparisons 
between treatment groups will be performed to ensure comparable results. 
12.5 Protocol Deviations 
All protocol deviations will be reported to the sponsor and recorded throughout the study. A 
tabulation of protocol deviations will be included in the final study report. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
53 
12.6 Compliance 
No formal evaluations of compliance are planned. 
12.7 Interim Analyses 
No interim analyses are planned. 
12.8 Additional Statistical Considerations 
12.8.1 Analysis Populations 
Approximately 210 adult subjects with moderate or severe psoriasis (defined as an IGA score 
of 3 or 4) will be enrolled and randomized in the study. With a 2:1 randomization ratio, it is 
anticipated that: 
x Approximately 140 subjects will be randomized to receive IDP-122 (HP 0.01%) 
Lotion 
x Approximately 70 subjects will be randomized to receive IDP-122 Vehicle Lotion 
Efficacy analyses will be performed using the intent-to-treat (ITT) population and the per 
protocol (PP) population. The ITT analysis set will be considered primary for the evaluation 
of efficacy. Safety analyses will be performed using the safety population. 
All subjects who are randomized and dispensed study drug will be included in the ITT 
analysis set. 
All subjects who are randomized, receive at least 1 confirmed dose of study drug and have at 
least 1 post-baseline safety assessment will be included in the safety analysis set. 
All subjects in the ITT analysis set who complete the Week 8 visit without any major 
protocol violations will be included in the PP analysis set. The PP population will include 
subjects in the ITT population who did not meet any of the following criteria: 
x Violated the inclusion/exclusion criteria 
x Used an interfering concomitant medication 
x Did not attend the Week 8 visit 
x Missed more than 1 post-baseline study visit prior to Week 8 
x Have not been compliant with the dosing regimen (i.e., subjects must apply 
80%-120% of the expected applications of study medication during participation 
in the study) 
x Out of visit window at the Week 8 visit by more than ± 5 days 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
54 
Subjects that discontinue from the study due to an adverse event related to study treatment or 
documented lack of treatment effect will be included in the PP population. Prior to breaking 
the blind, other additional criteria may be added to the list to accommodate for unforeseen 
events that occurred during the conduct of the trial that result in noteworthy study protocol 
violations.
The number of subjects in each analysis set will be summarized. Reasons for study 
withdrawal during the blinded study will be summarized using frequencies and percentages 
by treatment group. 
12.8.2 Sample Size Determination 
The following power calculations were computed using the observed Week 8 dichotomized 
IGA efficacy data in the ITT population from the Phase 2 study V01-118A-201. SAS PROC 
POWER with the Fisher’s exact test option was used to calculate the power for various 
sample sizes using a two-sided test with an alpha of 0.05. Table 5 presents the efficacy 
estimates derived from study V01-118A-201. 
Table 5. 
Percent Dichotomized IGA Success for Treatment Groups 
 
IDP-122* (IDP-118 
Monad (HP 0.01%) 
Lotion)
 IDP-122 
(IDP-118)**
Vehicle
Percent
Success 
33.3% 
9.7% 
Success was defined as at least a 2-grade improvement from Baseline in the IGA score and an IGA score 
equating to “Clear” or “Almost Clear”. 
*IDP-122 refers to the (IDP-118 Monad (HP 0.01%) Lotion) used in the V01-118A-201 Study 
**IDP 118 Vehicle composition used in the V01-118A-201 is equivalent to the vehicle that will be used in this 
study (IDP 122 Vehicle Lotion). 
One hundred forty (140) IDP-122 treated subjects and seventy (70) vehicle treated subjects 
will have greater than 95% power to detect a statistically significant outcome for a two-sided 
test with an alpha level of 0.05.
It was noted that the estimates extracted from the above studies are based on the LOCF 
method of handling missing values while the proposed Phase 3 analysis will account for 
missing values using multiple imputations. The power stated above sufficiently exceeds 95% 
which will compensate for the difference in handling of missing data. 
12.8.3 Handling of Missing Data 
The method of multiple imputation will be used (see Section 12.1.4).


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
55 
12.8.4 Multicenter Issues 
The study will be conducted at multiple investigational centers in North America with the 
intention of pooling the results for analysis. 
12.8.5 Multiplicity Issues 
Not applicable. 
12.8.6 Windowing Rules 
The timing of all study visits is relative to Baseline (Day 0). The Week 2 and 4 visits should 
occur within ± 3 days of the scheduled times, the Week 8 visit should occur within ± 5 days 
of the scheduled time, and Week 12 visits should occur within ± 7 days of the scheduled 
times. 
13 Quality Control and Quality Assurance 
13.1 Study Monitoring 
An Investigator Meeting or an initiation visit will be conducted with the principal 
investigator and study coordinators by sponsor and/or its designee. During this meeting, an 
extensive review and discussion of the protocol, the role of the study technician, all study 
procedures, source documents, and eCRFs will be conducted. Evaluation scales will be 
reviewed extensively and documentation of training will be recorded for training of sponsor-
approved evaluators. 
The study monitors/clinical research associates will be trained prior to study initiation. 
Following this training, an overview of the study disease and study material background will 
be understood. Specific monitoring guidelines and procedures to be followed during 
monitoring visits will also be utilized. During the course of the study, all data will be 100% 
source document verified by the monitors. All subject source records must be made available 
to the monitors. 
The conduct of the study will be closely monitored by the sponsor following GCP guidelines. 
The reports of these verifications will also be archived with the study report. In addition, 
inspections or on site audits may be carried out by local authorities or by the sponsor's 
Quality Assurance Department. The investigators will allow the sponsor's representatives and 
any regulatory agency to examine all study records, corresponding subject medical records, 
clinical dispensing records and storage area, and any other documents considered source 
documentation. The investigators agree to assist the representative, if required. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
56 
13.2 Audits and Inspections 
The study will be conducted under the sponsorship of Valeant in conformation with all 
appropriate local and federal regulations, as well as ICH guidelines. Interim and end of study 
audits of raw data, study files, and final report may be conducted by Valeant’s Quality 
Assurance Department or designee. 
The sponsor is responsible for implementing and maintaining quality assurance and quality 
control systems to ensure that studies are conducted and data are generated, documented, and 
reported in compliance with the protocol, GCP, and applicable regulatory requirements. In 
addition, the sponsor will be responsible for securing agreement from all involved parties to 
ensure direct access to all study related investigational centers, source data/documents, 
eCRFs, and reports for the purpose of monitoring and auditing by the sponsor, and inspection 
by domestic and foreign regulatory authorities. 
13.3 Data Quality Assurance 
All assessments performed will be accurately documented in the subject’s source documents 
and eCRFs. The investigator or designee will enter the information required by the protocol 
into the source documents and eCRFs provided by the sponsor or designee. Subjects will be 
identified in the eCRFs by their assigned subject number and initials only. 
The investigators must read the protocol thoroughly and must follow the instructions exactly. 
Any deviations should be agreed to by prior discussion between the sponsor and the 
investigator, with appropriate written protocol amendments made prior to implementing the 
agreed changes. Any amendment containing major modifications (particularly if it may 
involve an increased risk to the subjects) will be approved by the IRB before it may be 
implemented. No change in the conduct of the study can be instituted without written 
approval from the sponsor. 
14 Ethics and Administrative Issues 
14.1 Ethical Conduct of the Study 
This study will be conducted in accordance with the ethical principles originating from the 
Declaration of Helsinki, ICH guidelines, GCP, and in compliance with local regulatory 
requirements. The investigator agrees, when signing the protocol, to adhere to the 
instructions and procedures described in it and thereby to adhere to the principles of GCP. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
57 
14.2 Ethics Review 
This protocol, proposed informed consent form and other information to subjects, and all 
appropriate amendments will be properly reviewed and approved by an Institutional Review 
Board (IRB) or Independent Ethics Committee (IEC). A signed and dated notification of the 
IRB/IEC approval will be provided to the sponsor and investigator prior to study initiation. 
The name and occupation of the chairman and members of the IRB/IEC will be supplied to 
the sponsor. The investigator will provide required progress reports and report all SAEs to 
the IRB/IEC as required by the IRB/IEC. 
14.3 Written Informed Consent 
Written informed consent, in accordance with local clinical investigation regulations, must be 
obtained prior to participation in the study. The investigator or designee will discuss the 
purpose of the study with each subject, and provide a description of the study drug (including 
any potential and possible side effects) and the study procedures. Information must be given 
both in oral and written form. Subject information will be provided in a language 
understandable to the subject and may not include any language that appears to waive any of 
the subject‘s legal rights or appears to release the investigator, the sponsor or the institution 
from liability or negligence. 
The investigator will provide the prospective subject sufficient time to consider whether or 
not to participate, minimizing the possibility of coercion or undue influence and will discuss 
any questions the subject may have. The investigator will explain to the subject that 
participation in the study is voluntary and that withdrawal from the study is possible at any 
time without detriment to care. The consent must include acknowledgment that medical 
records and medical data derived from the study may be forwarded to the sponsor or to 
responsible local or federal authorities. 
No subject can enter the study or have any study related procedures performed before his/her 
written informed consent has been obtained. The original signed and dated informed consent 
form will be retained with the study records, and a copy of the signed form will be given to 
the subject. 
An informed consent template will be supplied by the sponsor. Any changes to the informed 
consent form must be agreed to by the sponsor or designee prior to submission to the 
IRB/IEC, and a copy of the approved version must be provided to the sponsor or designee 
after IRB/IEC approval. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
58 
14.4 Subject Data Protection 
Subject data will be protected by ensuring that no captured data contain subject names, 
addresses, telephone numbers, email addresses, or other direct personally identifying 
information. It is acknowledged that subject initials, demographics (including birthdates), 
medical histories, and prior concomitant medication uses, along with the name and address of 
the enrolling investigator may allow for personal identification of study participants. Other 
than where necessary to meet regulatory requirements, all data collected in this study will be 
presented in tabulated (i.e., aggregate) form and listings containing information that could be 
used to identify an individual subject will not be included in any public disclosures of the 
study data or the study results. 
14.5 Data Monitoring Committee 
Not applicable. 
14.6 Financial Disclosure 
Financial disclosures will be obtained from all investigators in order to document any 
potential conflicts of interest. 
14.7 Investigator Obligations 
The investigator agrees, when signing the protocol, to adhere to the instructions and 
procedures described in it and thereby to adhere to the principles of Good Clinical Practice 
(GCP).
14.8 Changes to the Protocol 
The investigators must read the protocol thoroughly and must follow the instructions exactly. 
Whenever possible, any planned deviations should be agreed to by prior discussion between 
the sponsor and the investigator, with appropriate documentation of sponsor approval prior to 
effecting the changes agreed upon. Any amendment to the protocol containing major 
modifications (particularly if it may involve an increased risk to the subjects) will be 
approved by the IRB before it may be implemented. No change in the conduct of the study 
can be instituted without written approval from the sponsor. 
14.9 Confidentiality/Publication of the Study 
All the data furnished to the investigator and his/her staff and all data obtained through this 
protocol will be regarded as confidential and proprietary in nature and will not be disclosed 
to any third party, except for the FDA or other regulatory body, without written consent from 
the sponsor. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
59 
15 Data Handling and Record Keeping 
15.1 Inspection of Records 
Investigators must maintain detailed records on all study subjects who are enrolled in the 
study or undergo screening. Data will be recorded in the subject’s source documents and in 
applicable study logs provided by the sponsor. Source documents include subject medical 
records, hospital charts, clinic charts, investigator subject study files, as well as the results of 
diagnostic tests (e.g., laboratory tests). All required data should be recorded in the study 
documentation completely for prompt data review. Upon study completion or at any other 
time specified by the sponsor or designee, the appropriate study documents must be 
submitted. 
The investigator must keep accurate separate records (source documentation) of all subject 
visits, being sure to include all pertinent study related information. At a minimum, this 
includes the following information: 
x A statement indicating that the subject has been enrolled in the study and the 
subject number 
x Date that informed consent was obtained 
x Evidence that the subject meets study eligibility requirements (e.g., medical 
history, screening evaluations) 
x Dates of all study related visits and results of any evaluations/procedures 
performed, including who performed each assessment at each visit 
x Use of any concurrent medications during the study 
x Documentation of study drug accountability 
x Any and all side effects and AEs must be thoroughly documented to conclusion 
x Results of any diagnostic tests conducted during the study 
x The date the subject exited the study and a statement indicating that the subject 
completed the study or was discontinued early, including the reason for 
discontinuation
Notes describing telephone conversations and all electronic mail with the subject or the 
sponsor (sponsor’s designee) concerning the study must be recorded or kept on file. All 
source documents must be made available to the sponsor and the sponsor’s designated 
monitor upon request. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
60 
15.2 Retention of Records 
The investigator should properly store and maintain all study records in accordance with 
sponsor directives. All records relating to the conduct of this study are to be retained by the 
investigator until notified by the sponsor in writing that the records may be destroyed. 
The investigator will allow representatives of the sponsor’s monitoring team, the governing 
IRB/IEC, the FDA, and other applicable regulatory agencies to inspect all study records, 
eCRFs, and corresponding portions of the subject’s clinic and/or hospital medical records at 
regular intervals throughout the study. These inspections are for the purpose of verifying 
adherence to the protocol, completeness and accuracy of the data being entered onto the 
eCRF, and compliance with FDA or other regulatory agency regulations. 
16 References
Not applicable. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
61 
17 Appendices
17.1 Subject Instruction Sheet 
A thin layer of study drug should be applied once daily at about the same time each day over 
the affected treatment areas indicated by the investigator for 8 weeks As a reminder, the face, 
scalp, axillae (armpit) and intertriginous (skinfold) areas will be excluded.
Specifically, subjects will squeeze a small amount of study drug (about the size of a pea) 
onto a fingertip and then spread a thin layer of the study drug over the affected treatment 
area. If necessary, additional pea-sized amounts of study drug may be applied in increments 
(one pea size gently rubbed over a treatment area at a time) to cover all affected treatment 
areas. 
The amount of study drug used by the subjects will be monitored by weighing each newly 
dispensed study drug container and weighing each returned study drug container at all 
applicable study visits. The maximum allowable weekly usage is 50 grams for this study. 
Be sure to wash your hands after you apply the product (unless the study doctor has 
instructed you to treat your palms). 
Reminders: 
x 
On study visit days please wait until after your study assessments are completed before 
application of the study drug or any approved moisturizers. Any retraining can be 
provided by site staff, if needed. 
x 
Avoid contact with the eyes, inside the nose, mouth and all mucous membranes. 
x 
THE TEST MATERIAL SHOULD BE USED ONLY BY THE PERSON FOR WHOM 
IT WAS PRESCRIBED and it should be kept out of the reach of children or others of 
limited capacity to read or understand. 
Store this at room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted 
between 15°C to 30°C (59°F to 86°F).
Containers of test material must be returned to the study facility, even if they are empty. 
Be sure to complete the diary calendar each day to document applications and also note any 
missed doses; and bring the completed diary to each study visit. 
Continue to use the same study doctor approved non-medicated cleansers, moisturizers and 
sunscreens throughout the study. Avoid or minimize unnecessary sun exposure. Also for 
further ultraviolet protection use protective clothing such as broad brimmed hats as needed. 
 
      
It is important that you inform the study site about any medications (i.e., prescriptions, over-
the-counter medications, street drugs, or herbal medications) that you have taken during the 
study.
If you have any questions or have a potential research-related side effect or injury you may 
contact ________________________ at _________________. 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
62 
17.2 Cleanser, Moisturizer and Sunscreen Use Guidelines 
Investigators may use their discretion on what cleansers and moisturizer products each 
subject may use in the treatment areas during the study. Subjects may only use Investigator 
approved non-medicated products on the treatment areas. Information regarding products 
used should be captured in the source document and recorded on the Prior and Concomitant 
Medications or Therapies eCRF. 
Approved Cleanser Examples: 
ዘCeraVe cleanser 
ዘCetaphil daily cleaner and gentle cleansing bar 
ዘPurpose gentle cleansing wash 
ዘInvestigator-approved non-medicated cleanser 
Approved Moisturizer Examples: 
ዘCeraVe Cream or Lotion 
ዘMoisturel cream or lotion 
ዘNutraderm 
ዘCetaphil lotion or cream 
ዘDML
ዘEucerin lotion or cream 
ዘPurpose
Subjects should avoid excessive sun exposure, but when this can’t be avoided, an approved 
sunscreen may be used. Also for further ultraviolet protection use protective clothing, such as 
broad brimmed hats, as needed. 
Approved Sunscreen Examples:  
x Banana Boat Sport Sunblock Lotion (SPF 15, 30+ or 50)
x Neutrogena UVA/UVB (SPF 30 or 45)
x Neutrogena Sensitive Skin Sunblock Lotion (SPF 17)
x Neutrogena Healthy Defense Oil-Free Sunblock Lotion (SPF 30 or 45) 
x Coppertone Water Babies UVA/UVB Sunblock Lotion (SPF45) 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
63 
17.3 Dermatology Life Quality Index (DLQI) Questionnaire 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
64 
17.4 Amendment Summary of Changes 
Section 
Original Protocol Previously 
Read: 
Protocol Amendment 1 Currently 
Reads:
2.0 
Study Synopsis 
Methodology 
7.1 
Overall Study Design and 
Plan: Description 
17.1 Subject Instruction 
Sheet 
The subjects will be instructed to 
avoid exposure to direct sunlight to 
prevent sunburn. 
The subjects will be instructed to avoid 
exposure to direct sunlight, artificial 
ultraviolet light sources and to use 
protective clothing to prevent sunburn. 
2.0 
Study Synopsis 
Methodology 
11.1  
Visit Descriptions 
7.1 
Overall Study Design and 
Plan: Description 
17.1 
Subject Instruction Sheet 
During, the study, subjects will be 
allowed to use investigator 
approved non medicated cleansers 
and moisturizers; no sunscreens or 
other skin care products will be 
permitted on the treatment areas. 
During the study, subjects will be 
allowed to use investigator approved 
non-medicated cleansers, moisturizers 
and sunscreens; no other skin care 
products will be permitted on the 
treatment areas. 
2.0 
Study Synopsis 
Methodology 
Key Exclusion Criteria 
8.2  
Subject Exclusion Criteria 
7. Has used any phototherapy 
(including laser), 
photochemotherapy, or systemic 
psoriasis therapy (such as systemic 
corticosteroids, methotrexate, 
retinoids or cyclosporine) within 4 
weeks prior to the Baseline visit. 
7. Has used any phototherapy (including 
laser), photochemotherapy, or non-
biologic systemic psoriasis therapy (such 
as newer oral psoriasis medications (eg 
Otezla), systemic corticosteroids, 
methotrexate, retinoids or cyclosporine) 
within 4 weeks prior to the Baseline 
visit. 
2.0 
Study Synopsis 
Methodology 
Application instructions 
9.5 
Treatment Compliance 
10.1. 
Administration 
17.1 
Subject Instruction Sheet 
N/A  
The maximum allowable weekly usage 
is 50 grams for this study. 
2.0 
Study Synopsis 
Methodology 
Inferential Statistics 
Secondary Efficacy 
12.1.2
Secondary Efficacy 
N/A 
• Percentage of subjects who show at 
least a 2 grade improvement and reach 
Clear to Almost Clear at Week 6 for 
IDP-122 Lotion versus IDP-122 Vehicle 
Lotion 
9.4 
Prior and Prohibited 
Concomitant Medication 
of Therapy 
• Within 4 weeks prior to the 
Baseline visit, subjects must not 
have used any phototherapy 
(including laser), 
photochemotherapy, or systemic 
psoriasis therapy (such as systemic 
corticosteroids, methotrexate, 
retinoids or cyclosporine) 
• Within 4 weeks prior to the Baseline 
visit, subjects must not have used any 
phototherapy (including laser), 
photochemotherapy, or non-biologic 
systemic psoriasis therapy (such as 
newer oral psoriasis medications (eg 
Otezla), systemic corticosteroids, 
methotrexate, retinoids or cyclosporine) 


Protocol V01-122A-302, IDP-122 Phase 3 
Valeant Research & Development 
Amendment 1, Clinical Study Protocol, 14 October 2015 
 
CONFIDENTIAL 
65 
Section
Original Protocol Previously 
Read:
Protocol Amendment 1 Currently 
Reads:
9.4 
Prior and Prohibited 
Concomitant Medication 
of Therapy 
Subjects are allowed only the use 
of investigator approved non-
medicated cleansers and 
moisturizers in the treatment areas. 
Subjects are allowed only the use of 
investigator approved non-medicated 
cleansers, moisturizers and sunscreens in 
the treatment areas. 
10.1.1
Packaging and Labeling 
IDP-122 Lotion will be packaged 
in study drug kits. 
IDP-122 Lotion and IDP 122 Vehicle 
Lotion will be packaged in identical 
study drug kits. 
17.1 
Subject Instruction Sheet 
17.2 
Cleansers, moisturizers 
and  sunscreen Use 
Guidelines 
Also for further ultraviolet protection, 
use protective clothing and broad 
brimmed hats as needed. 
9.5 
Treatment Compliance 
The subjects will bring the 
containers dispensed at each on 
treatment visit to the next 
subsequent study visit. 
The subjects will bring the containers 
dispensed at each on-site treatment visit 
to the next subsequent study visit.
11.1.2
Baseline Visit (Day 0) 
12. Take photographs of selected 
target lesion and choose one other 
lesion to photograph. 
The selected lesions should be 
photographed consistently for all 
subsequent visits. 
N/A (removed as not applicable on this 
study)